Acute	O
leukemia	O
with	O
promyelocytic	O
features	O
in	O
PML/RARalpha	O
transgenic	O
mice	O
.	O

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
associated	O
with	O
reciprocal	O
chromosomal	O
translocations	O
involving	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
RARalpha	I-DNA
)	I-DNA
locus	I-DNA
on	O
chromosome	B-DNA
17	I-DNA
.	O

In	O
the	O
majority	O
of	O
cases	O
,	O
RARalpha	B-protein
translocates	O
and	O
fuses	O
with	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
(	I-DNA
PML	I-DNA
)	I-DNA
gene	I-DNA
located	O
on	O
chromosome	B-DNA
15	I-DNA
.	O

The	O
resulting	O
fusion	B-DNA
genes	I-DNA
encode	O
the	O
two	O
structurally	O
unique	O
PML/RARalpha	B-protein
and	O
RARalpha/PML	B-protein
fusion	I-protein
proteins	I-protein
as	O
well	O
as	O
aberrant	B-protein
PML	I-protein
gene	I-protein
products	I-protein
,	O
the	O
respective	O
pathogenetic	O
roles	O
of	O
which	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
the	O
PML/RARalpha	B-protein
fusion	I-protein
protein	I-protein
is	O
specifically	O
expressed	O
in	O
the	O
myeloid-promyelocytic	B-cell_type
lineage	I-cell_type
.	O

During	O
their	O
first	O
year	O
of	O
life	O
,	O
all	O
the	O
PML/	O
RARalpha	B-protein
transgenic	O
mice	O
have	O
an	O
abnormal	O
hematopoiesis	O
that	O
can	O
best	O
be	O
described	O
as	O
a	O
myeloproliferative	O
disorder	O
.	O

Between	O
12	O
and	O
14	O
months	O
of	O
age	O
,	O
10	O
%	O
of	O
them	O
develop	O
a	O
form	O
of	O
acute	O
leukemia	O
with	O
a	O
differentiation	O
block	O
at	O
the	O
promyelocytic	O
stage	O
that	O
closely	O
mimics	O
human	O
APL	O
even	O
in	O
its	O
response	O
to	O
retinoic	O
acid	O
.	O

Our	O
results	O
are	O
conclusive	O
in	O
vivo	O
evidence	O
that	O
PML/RARalpha	B-protein
plays	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
APL	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

94	NULL
,	NULL
pp	NULL
.	NULL

5302-5307	NULL
,	NULL
May	NULL
1997	NULL
Medical	NULL
Sciences	NULL
Acute	NULL
leukemia	NULL
with	NULL
promyelocytic	NULL
features	NULL
in	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
mice	NULL
Lr-ZHEN	NULL
HE**	NULL
,	NULL
RoBERTA	NULL
RIvI*	NULL
,	NULL
DaNIELA	NULL
PERUZzZI*	NULL
,	NULL
PIER	NULL
GIUsEPPE	NULL
PELIiccI§	NULL
,	NULL
VERA	NULL
SoaREs*	NULL
,	NULL
GIORGIO	NULL
CATTORETTI	NULL
!	NULL

,	NULL
anp	NULL
PIER	NULL
PAoLO	NULL
PANDOLFI*\	NULL
*Department	NULL
of	NULL
Human	NULL
Genetics	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
Molecular	NULL
Biology	NULL
and	NULL
Cell	NULL
Biology	NULL
Programs	NULL
,	NULL
Sloan-Kettering	NULL
Institute	NULL
,	NULL
1275	NULL
York	NULL
Avenue	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
10021	NULL
;	NULL
$	NULL
Istituto	NULL
Oncologico	NULL
Europeo	NULL
,	NULL
20141	NULL
Milan	NULL
,	NULL
Italy	NULL
;	NULL
and	NULL
l	NULL
``	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Columbia	NULL
University	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10032	NULL
Communicated	NULL
by	NULL
Paul	NULL
A	NULL
.	NULL

Marks	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
March	NULL
3	NULL
,	NULL
1997	NULL
(	NULL
received	NULL
for	NULL
review	NULL
January	NULL
14	NULL
,	NULL
1997	NULL
)	NULL
ABSTRACT	NULL
Acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
is	NULL
associated	NULL
with	NULL
reciprocal	NULL
chromosomal	NULL
translocations	NULL
involy-ing	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
«	NULL
(	NULL
RAR	NULL
«	NULL
)	NULL
locus	NULL
on	NULL
chromosome	NULL
17	NULL
.	NULL

In	NULL
the	NULL
majority	NULL
of	NULL
cases	NULL
,	NULL
RARa	NULL
translocates	NULL
and	NULL
fuses	NULL
with	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
PML	NULL
)	NULL
gene	NULL
located	NULL
on	NULL
chromosome	NULL
15	NULL
.	NULL

The	NULL
resulting	NULL
fusion	NULL
genes	NULL
encode	NULL
the	NULL
two	NULL
structurally	NULL
unique	NULL
PML	NULL
/RARa	NULL
and	NULL
RARa/PML	NULL
fusion	NULL
proteins	NULL
as	NULL
well	NULL
as	NULL
aberrant	NULL
PML	NULL
gene	NULL
products	NULL
,	NULL
the	NULL
respective	NULL
pathoge-netic	NULL
roles	NULL
of	NULL
which	NULL
have	NULL
not	NULL
been	NULL
elucidated	NULL
.	NULL

We	NULL
have	NULL
generated	NULL
transgenic	NULL
mice	NULL
in	NULL
which	NULL
the	NULL
PML	NULL
/RARa	NULL
fusion	NULL
protein	NULL
is	NULL
specifically	NULL
expressed	NULL
in	NULL
the	NULL
myeloid-promyelocytic	NULL
lineage	NULL
.	NULL

During	NULL
their	NULL
first	NULL
year	NULL
of	NULL
life	NULL
,	NULL
all	NULL
the	NULL
PML/RARa	NULL
«	NULL
transgenic	NULL
mice	NULL
have	NULL
an	NULL
abnormal	NULL
hematopoiesis	NULL
that	NULL
can	NULL
best	NULL
be	NULL
described	NULL
as	NULL
a	NULL
myeloproliferative	NULL
disorder	NULL
.	NULL

Between	NULL
12	NULL
and	NULL
14	NULL
months	NULL
of	NULL
age	NULL
,	NULL
10	NULL
%	NULL
of	NULL
them	NULL
develop	NULL
a	NULL
form	NULL
of	NULL
acute	NULL
leukemia	NULL
with	NULL
a	NULL
differentiation	NULL
block	NULL
at	NULL
the	NULL
promyelocytic	NULL
stage	NULL
that	NULL
closely	NULL
mimics	NULL
human	NULL
APL	NULL
even	NULL
in	NULL
its	NULL
response	NULL
to	NULL
retinoic	NULL
acid	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
conclusive	NULL
in	NULL
vivo	NULL
evidence	NULL
that	NULL
PML/RARa	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
APL	NULL
.	NULL

Acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
,	NULL
the	NULL
M3	NULL
subtype	NULL
of	NULL
the	NULL
French-American-British	NULL
classification	NULL
of	NULL
acute	NULL
myeloid	NULL
leukemias	NULL
(	NULL
1	NULL
)	NULL
,	NULL
is	NULL
characterized	NULL
by	NULL
three	NULL
distinct	NULL
and	NULL
unique	NULL
features	NULL
:	NULL
(	NULL
?	NULL
)	NULL

the	NULL
accumulation	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
(	NULL
BM	NULL
)	NULL
of	NULL
tumor	NULL
cells	NULL
with	NULL
promyelocytic	NULL
features	NULL
;	NULL
(	NULL
#	NULL
)	NULL
the	NULL
invariable	NULL
association	NULL
with	NULL
specific	NULL
translocations	NULL
that	NULL
always	NULL
involve	NULL
chromosome	NULL
17	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

2	NULL
)	NULL
;	NULL
and	NULL
(	NULL
i	NULL
)	NULL
the	NULL
exquisite	NULL
sensitivity	NULL
of	NULL
APL	NULL
blasts	NULL
to	NULL
the	NULL
differentiating	NULL
action	NULL
of	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
(	NULL
reviewed	NULL
in	NULL
refs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

From	NULL
this	NULL
point	NULL
of	NULL
view	NULL
,	NULL
APL	NULL
has	NULL
become	NULL
the	NULL
paradigm	NULL
for	NULL
therapeutic	NULL
approaches	NULL
using	NULL
differentiating	NULL
agents	NULL
.	NULL

In	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
patients	NULL
,	NULL
APL	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
reciprocal	NULL
translocation	NULL
between	NULL
chromosomes	NULL
15	NULL
and	NULL
17	NULL
(	NULL
5-8	NULL
)	NULL
.	NULL

At	NULL
the	NULL
molecular	NULL
level	NULL
,	NULL
the	NULL
breakpoint	NULL
on	NULL
chromosome	NULL
17	NULL
lies	NULL
within	NULL
the	NULL
RA	NULL
receptor	NULL
a	NULL
(	NULL
RARa	NULL
)	NULL
locus	NULL
.	NULL

The	NULL
breakpoints	NULL
on	NULL
chromosome	NULL
15	NULL
cluster	NULL
within	NULL
the	NULL
PML	NULL
locus	NULL
[	NULL
for	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
9-12	NULL
)	NULL
]	NULL
.	NULL

In	NULL
rare	NULL
cases	NULL
,	NULL
the	NULL
translocation	NULL
involves	NULL
chromosome	NULL
11	NULL
instead	NULL
of	NULL
chromosome	NULL
15	NULL
,	NULL
and	NULL
a	NULL
newly	NULL
identified	NULL
gene	NULL
named	NULL
promyelocytic	NULL
leukemia	NULL
zinc	NULL
finger	NULL
(	NULL
PLZF	NULL
)	NULL
instead	NULL
of	NULL
PML	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
only	NULL
four	NULL
cases	NULL
does	NULL
the	NULL
translocation	NULL
involve	NULL
chromosome	NULL
5	NULL
and	NULL
the	NULL
nucleophosmin	NULL
gene	NULL
(	NULL
NPM	NULL
)	NULL
or	NULL
chromosome	NULL
11	NULL
and	NULL
the	NULL
NUMA	NULL
gene	NULL
(	NULL
refs	NULL
.	NULL

14	NULL
and	NULL
15	NULL
and	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

The	NULL
common	NULL
feature	NULL
of	NULL
the	NULL
four	NULL
translocations	NULL
is	NULL
the	NULL
involvement	NULL
of	NULL
chromosome	NULL
17	NULL
and	NULL
of	NULL
the	NULL
RARa	NULL
locus	NULL
(	NULL
2	NULL
)	NULL
.	NULL

The	NULL
15	NULL
;	NULL
17	NULL
translocation	NULL
results	NULL
in	NULL
the	NULL
production	NULL
of	NULL
two	NULL
fusion	NULL
genes	NULL
that	NULL
encode	NULL
a	NULL
PML	NULL
/RARa	NULL
fusion	NULL
protein	NULL
(	NULL
9-11	NULL
)	NULL
,	NULL
an	NULL
RARa/PML	NULL
fusion	NULL
protein	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
an	NULL
aberrant	NULL
PML	NULL
protein	NULL
that	NULL
lacks	NULL
the	NULL
PML	NULL
C-terminal	NULL
end	NULL
and	NULL
its	NULL
phosphorylation	NULL
site	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Be	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

Copyright	NULL
©	NULL
1997	NULL
by	NULL
Tar	NULL
Narronat	NULL
Acapemy	NULL
or	NULL
Sciences	NULL
or	NULL
THE	NULL
USA	NULL
0027-8424	NULL
/97/945302-6	NULL
$	NULL
2.00/0	NULL
PNAS	NULL
is	NULL
available	NULL
online	NULL
at	NULL
http	NULL
:	NULL
//www.pnas.org	NULL
.	NULL

5302	NULL
cause	NULL
the	NULL
PML	NULL
/RARa	NULL
hybrid	NULL
retains	NULL
most	NULL
of	NULL
the	NULL
functional	NULL
domains	NULL
of	NULL
its	NULL
parental	NULL
proteins	NULL
and	NULL
can	NULL
heterodimerize	NULL
with	NULL
PML	NULL
and	NULL
retinoid-X-receptor	NULL
(	NULL
RXR	NULL
)	NULL
,	NULL
the	NULL
chimeric	NULL
proteins	NULL
might	NULL
act	NULL
as	NULL
doubly	NULL
dominant	NULL
negative	NULL
oncogenic	NULL
products	NULL
,	NULL
interfering	NULL
with	NULL
both	NULL
PML	NULL
and	NULL
RAR/RXR	NULL
pathways	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

This	NULL
expectation	NULL
has	NULL
been	NULL
corroborated	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
,	NULL
while	NULL
PML	NULL
is	NULL
normally	NULL
concentrated	NULL
within	NULL
discrete	NULL
speckled	NULL
nuclear	NULL
structures	NULL
called	NULL
PML	NULL
nuclear	NULL
bodies	NULL
(	NULL
NBs	NULL
)	NULL
[	NULL
also	NULL
called	NULL
Kremer	NULL
Bodies	NULL
,	NULL
ND10	NULL
,	NULL
or	NULL
PODs	NULL
(	NULL
for	NULL
PML	NULL
oncogenic	NULL
domains	NULL
)	NULL
]	NULL
,	NULL
this	NULL
normal	NULL
localization	NULL
pattern	NULL
is	NULL
abolished	NULL
in	NULL
promyelocytes	NULL
from	NULL
APL	NULL
patients	NULL
and	NULL
in	NULL
the	NULL
promyelocytic	NULL
cell	NULL
line	NULL
NB4	NULL
,	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
PML	NULL
In	NULL
these	NULL
cases	NULL
,	NULL
aberrant	NULL
structures	NULL
,	NULL
within	NULL
which	NULL
PML	NULL
,	NULL
RARa	NULL
,	NULL
RXRa	NULL
,	NULL
and	NULL
the	NULL
PML	NULL
/RARa	NULL
«	NULL
fusion	NULL
protein	NULL
colocalize	NULL
,	NULL
become	NULL
apparent	NULL
(	NULL
19-21	NULL
)	NULL
.	NULL

PML	NULL
is	NULL
specifically	NULL
up-regulated	NULL
at	NULL
the	NULL
tran-scriptional	NULL
level	NULL
by	NULL
interferons	NULL
,	NULL
and	NULL
its	NULL
overexpression	NULL
is	NULL
accompanied	NULL
by	NULL
growth	NULL
suppression	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

All	NULL
these	NULL
observations	NULL
taken	NULL
together	NULL
would	NULL
suggest	NULL
that	NULL
the	NULL
deregulation	NULL
of	NULL
the	NULL
PML	NULL
pathway	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
promyelocytic	NULL
leukemogenesis	NULL
and	NULL
that	NULL
the	NULL
disruption	NULL
of	NULL
this	NULL
activity	NULL
by	NULL
PML/	NULL
RARa	NULL
could	NULL
result	NULL
in	NULL
the	NULL
expansion	NULL
of	NULL
the	NULL
APL	NULL
blasts	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
possible	NULL
role	NULL
of	NULL
RARa	NULL
in	NULL
the	NULL
control	NULL
of	NULL
myeloid	NULL
terminal	NULL
differentiation	NULL
(	NULL
24-26	NULL
)	NULL
suggests	NULL
that	NULL
the	NULL
concomitant	NULL
interference	NULL
of	NULL
PML	NULL
/RARa	NULL
with	NULL
RARa/RXRa	NULL
«	NULL
function	NULL
could	NULL
lead	NULL
to	NULL
the	NULL
block	NULL
of	NULL
maturation	NULL
at	NULL
the	NULL
promyelocytic	NULL
stage	NULL
observed	NULL
in	NULL
APL	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
PML/RARa	NULL
protein	NULL
is	NULL
capable	NULL
of	NULL
blocking	NULL
the	NULL
terminal	NULL
differentiation	NULL
of	NULL
myeloid	NULL
precursor	NULL
cells	NULL
such	NULL
as	NULL
U937	NULL
,	NULL
HL60	NULL
,	NULL
or	NULL
K562	NULL
induced	NULL
by	NULL
certain	NULL
stimuli	NULL
,	NULL
including	NULL
vitamin	NULL
Ds	NULL
;	NULL
and	NULL
transforming	NULL
growth	NULL
factor	NULL
type	NULL
B	NULL
.	NULL

However	NULL
,	NULL
the	NULL
information	NULL
available	NULL
on	NULL
the	NULL
function	NULL
of	NULL
the	NULL
APL-specific	NULL
chimeric	NULL
products	NULL
relies	NULL
thus	NULL
far	NULL
only	NULL
on	NULL
data	NULL
derived	NULL
from	NULL
leukemic	NULL
cell	NULL
lines	NULL
,	NULL
which	NULL
are	NULL
obviously	NULL
not	NULL
the	NULL
ideal	NULL
system	NULL
for	NULL
the	NULL
study	NULL
of	NULL
oncogenic	NULL
transformation	NULL
(	NULL
27-29	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
there	NULL
is	NULL
no	NULL
direct	NULL
proof	NULL
that	NULL
the	NULL
PML	NULL
/RARa	NULL
and	NULL
RARa	NULL
«	NULL
/PML	NULL
fusion	NULL
proteins	NULL
,	NULL
and	NULL
the	NULL
aberrant	NULL
PML	NULL
protein	NULL
,	NULL
can	NULL
cause	NULL
APL	NULL
,	NULL
and	NULL
their	NULL
individual	NULL
relative	NULL
contributions	NULL
to	NULL
producing	NULL
the	NULL
leukemic	NULL
phenotype	NULL
have	NULL
not	NULL
been	NULL
elucidated	NULL
.	NULL

Here	NULL
we	NULL
provide	NULL
evidence	NULL
that	NULL
the	NULL
myeloid-promyelocytic	NULL
restricted	NULL
expression	NULL
of	NULL
the	NULL
PML/	NULL
RARa	NULL
fusion	NULL
protein	NULL
in	NULL
the	NULL
transgenic	NULL
mouse	NULL
results	NULL
in	NULL
acute	NULL
leukemia	NULL
characterized	NULL
by	NULL
the	NULL
specific	NULL
differentiation	NULL
block	NULL
at	NULL
Abbreviations	NULL
:	NULL
APL	NULL
,	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
;	NULL
RA	NULL
,	NULL
retinoic	NULL
acid	NULL
;	NULL
RARa	NULL
,	NULL
RA	NULL
receptor	NULL
a	NULL
;	NULL
PML	NULL
,	NULL
promyelocytic	NULL
leukemia	NULL
;	NULL
PLZF	NULL
,	NULL
promyelocytic	NULL
leukemia	NULL
zinc	NULL
finger	NULL
;	NULL
NPM	NULL
,	NULL
nucleophosmin	NULL
;	NULL
NBs	NULL
,	NULL
nuclear	NULL
bodies	NULL
;	NULL
hCG	NULL
,	NULL
human	NULL
cathepsin-G	NULL
;	NULL
RT	NULL
,	NULL
reverse	NULL
transcriptase	NULL
;	NULL
WBC	NULL
,	NULL
white	NULL
blood	NULL
cell	NULL
(	NULL
s	NULL
)	NULL
;	NULL
PB	NULL
,	NULL
peripheral	NULL
blood	NULL
;	NULL
BM	NULL
,	NULL
bone	NULL
marrow	NULL
;	NULL
MPO	NULL
,	NULL
myeloperoxidase	NULL
;	NULL
BFU-E	NULL
,	NULL
burst-forming	NULL
units-erythroid	NULL
;	NULL
CFU-E	NULL
,	NULL
-GM	NULL
,	NULL
and	NULL
-GEMM	NULL
,	NULL
colony-forming	NULL
units-erythroid	NULL
,	NULL
-granulocyte/	NULL
macrophage	NULL
,	NULL
-granulocyte/erythroid/macrophage/megakaryocyte	NULL
,	NULL
respectively	NULL
;	NULL
NBT	NULL
,	NULL
nitro	NULL
blue	NULL
tetrazolium	NULL
;	NULL
RXR	NULL
,	NULL
retinoid-X-receptor	NULL
.	NULL

1L.-Z.H	NULL
.	NULL

and	NULL
C.T	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

#	NULL
On	NULL
leave	NULL
of	NULL
absence	NULL
from	NULL
Istituto	NULL
di	NULL
Genetica	NULL
Biochimica	NULL
ed	NULL
Evolu-zionistica	NULL
,	NULL
Consiglio	NULL
Nazionale	NULL
delle	NULL
Ricerche	NULL
,	NULL
27100	NULL
Pavia	NULL
,	NULL
Italy	NULL
.	NULL

!	NULL

To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

e-mail	NULL
:	NULL
p-pandolfi	NULL
@	NULL
ski.mskec.org	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
He	NULL
et	NULL
al	NULL
.	NULL

the	NULL
promyelocytic	NULL
stage	NULL
that	NULL
defines	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Construction	NULL
of	NULL
the	NULL
Transgene	NULL
.	NULL

To	NULL
generate	NULL
the	NULL
human	NULL
cathepsin-G	NULL
(	NULL
hCG	NULL
)	NULL
minigene	NULL
expression	NULL
vector	NULL
,	NULL
we	NULL
screened	NULL
a	NULL
human	NULL
genomic	NULL
placenta	NULL
library	NULL
with	NULL
a	NULL
hCG	NULL
full-length	NULL
cDNA	NULL
probe	NULL
generated	NULL
by	NULL
reverse	NULL
transcriptase	NULL
(	NULL
RT	NULL
)	NULL
-PCR	NULL
and	NULL
obtained	NULL
four	NULL
overlapping	NULL
phages	NULL
which	NULL
spanned	NULL
the	NULL
hCG	NULL
locus	NULL
.	NULL

A	NULL
3.3-kb	NULL
BamHI-EcoRI	NULL
fragment	NULL
that	NULL
contains	NULL
the	NULL
hCG	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
and	NULL
its	NULL
promoter	NULL
and	NULL
a	NULL
6-kb	NULL
Sell-BamHI	NULL
fragment	NULL
that	NULL
contains	NULL
the	NULL
coding	NULL
and	NULL
the	NULL
3	NULL
'	NULL
flanking	NULL
regions	NULL
were	NULL
subcloned	NULL
into	NULL
Bluescript	NULL
plasmids	NULL
(	NULL
Stratagene	NULL
)	NULL
and	NULL
named	NULL
pT2BE3	NULL
and	NULL
pT4BS6	NULL
,	NULL
respectively	NULL
.	NULL

Two	NULL
pairs	NULL
of	NULL
PCR	NULL
primers	NULL
(	NULL
AF-HR	NULL
and	NULL
Sall	NULL
BE-LR	NULL
;	NULL
AF	NULL
,	NULL
CTTGCTTTGCTGGAGTATTCTG	NULL
;	NULL
HR	NULL
,	NULL
TTTCCTGAAAGGCTGCCCAG	NULL
;	NULL
Sell	NULL
BF	NULL
,	NULL
GTCGACAGC-CACTCCTGCTTCTGCTG	NULL
;	NULL
LR	NULL
,	NULL
GTCCAATTCAAGAC-CACGTGGGACT	NULL
;	NULL
see	NULL
ref	NULL
.	NULL

30	NULL
)	NULL
were	NULL
used	NULL
to	NULL
amplify	NULL
a	NULL
0.3-kb	NULL
fragment	NULL
ending	NULL
one	NULL
base	NULL
before	NULL
the	NULL
ATG	NULL
and	NULL
a	NULL
0.4-kb	NULL
fragment	NULL
starting	NULL
one	NULL
base	NULL
after	NULL
the	NULL
ATG	NULL
of	NULL
hCG	NULL
gene	NULL
with	NULL
an	NULL
artificial	NULL
Sall	NULL
site	NULL
at	NULL
its	NULL
5	NULL
``	NULL
end	NULL
.	NULL

The	NULL
two	NULL
PCR	NULL
products	NULL
were	NULL
cloned	NULL
into	NULL
Bluescript	NULL
,	NULL
sequenced	NULL
to	NULL
exclude	NULL
PCR	NULL
amplification	NULL
errors	NULL
,	NULL
and	NULL
named	NULL
pBST	NULL
and	NULL
pB15	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
3.3-kb	NULL
5°	NULL
BamHI-EcoRI	NULL
fragment	NULL
from	NULL
pT2BE3	NULL
was	NULL
fused	NULL
to	NULL
the	NULL
pBST	NULL
fragment	NULL
to	NULL
reconstruct	NULL
the	NULL
5	NULL
'	NULL
of	NULL
the	NULL
gene	NULL
just	NULL
before	NULL
the	NULL
ATG	NULL
and	NULL
named	NULL
HB33	NULL
.	NULL

A	NULL
BamHI-Sall	NULL
fragment	NULL
from	NULL
HB33	NULL
was	NULL
cloned	NULL
at	NULL
a	NULL
Sell	NULL
site	NULL
into	NULL
the	NULL
plasmid	NULL
pBSNN	NULL
,	NULL
into	NULL
which	NULL
a	NULL
Tk-Neo	NULL
cassette	NULL
had	NULL
been	NULL
cloned	NULL
for	NULL
the	NULL
purpose	NULL
of	NULL
selection	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
a	NULL
3-kb	NULL
Pmil-BamHI	NULL
fragment	NULL
containing	NULL
the	NULL
coding	NULL
and	NULL
3	NULL
'	NULL
flanking	NULL
regions	NULL
of	NULL
the	NULL
hCG	NULL
excised	NULL
from	NULL
pT4BS6	NULL
was	NULL
fused	NULL
at	NULL
the	NULL
3	NULL
'	NULL
of	NULL
pB15	NULL
at	NULL
a	NULL
Pll	NULL
site	NULL
to	NULL
reconstruct	NULL
the	NULL
3	NULL
'	NULL
of	NULL
the	NULL
gene	NULL
just	NULL
after	NULL
the	NULL
ATG	NULL
.	NULL

A	NULL
Clal-BamHI	NULL
fragment	NULL
from	NULL
this	NULL
vector	NULL
was	NULL
cloned	NULL
into	NULL
pBSNN	NULL
at	NULL
the	NULL
Ciel	NULL
site	NULL
,	NULL
thus	NULL
reconstructing	NULL
a	NULL
cathepsin-G	NULL
minigene	NULL
in	NULL
which	NULL
the	NULL
ATG	NULL
was	NULL
replaced	NULL
by	NULL
two	NULL
unique	NULL
cloning	NULL
sites	NULL
,	NULL
ClaI	NULL
and	NULL
Sall	NULL
(	NULL
hLCG-GAG	NULL
vector	NULL
)	NULL
.	NULL

This	NULL
plasmid	NULL
vector	NULL
is	NULL
11	NULL
kb	NULL
long	NULL
and	NULL
can	NULL
be	NULL
linearized	NULL
before	NULL
transfection	NULL
with	NULL
use	NULL
of	NULL
a	NULL
unique	NULL
BamHI	NULL
site	NULL
.	NULL

Subsequently	NULL
,	NULL
a	NULL
blunt-ended	NULL
3.15-kb	NULL
NotI-EcoRI	NULL
fragment	NULL
spanning	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
cDNA	NULL
(	NULL
9	NULL
)	NULL
,	NULL
and	NULL
the	NULL
Lac-Z	NULL
cDNA	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
blunt-ended	NULL
artificial	NULL
Sall	NULL
site	NULL
of	NULL
the	NULL
hCG-GAG	NULL
vector	NULL
(	NULL
hCG-PML/RARa	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
mRNAs	NULL
are	NULL
processed	NULL
and	NULL
stabilized	NULL
by	NULL
the	NULL
splicing	NULL
events	NULL
occurring	NULL
between	NULL
the	NULL
various	NULL
hCG	NULL
exons	NULL
,	NULL
and	NULL
are	NULL
polya-denylylated	NULL
.	NULL

Finally	NULL
,	NULL
BarmHI-NofI	NULL
fragments	NULL
from	NULL
these	NULL
constructs	NULL
were	NULL
purified	NULL
for	NULL
egg	NULL
injection	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
(	NULL
31	NULL
)	NULL
.	NULL

DNA	NULL
and	NULL
RNA	NULL
Analysis	NULL
.	NULL

Genomic	NULL
DNA	NULL
extracted	NULL
from	NULL
mouse	NULL
tails	NULL
was	NULL
digested	NULL
with	NULL
EcoRI	NULL
and	NULL
HindIII	NULL
and	NULL
hybridized	NULL
with	NULL
probe	NULL
CT	NULL
,	NULL
a	NULL
250-bp	NULL
HindIII-Xbal	NULL
hCG	NULL
genomic	NULL
fragment	NULL
,	NULL
and	NULL
probe	NULL
HS1	NULL
,	NULL
a	NULL
1-kb	NULL
hCG	NULL
genomic	NULL
fragment	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

A	NULL
murine	NULL
PML	NULL
EcoRI-Apal	NULL
genomic	NULL
fragment	NULL
(	NULL
PML	NULL
probe	NULL
A	NULL
)	NULL
(	NULL
unpub-lished	NULL
work	NULL
)	NULL
was	NULL
used	NULL
to	NULL
normalize	NULL
and	NULL
determine	NULL
the	NULL
number	NULL
of	NULL
copies	NULL
of	NULL
the	NULL
transgene	NULL
with	NULL
the	NULL
help	NULL
of	NULL
a	NULL
PhosphorImager	NULL
densitometer	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

For	NULL
Northern	NULL
blot	NULL
analysis	NULL
,	NULL
total	NULL
RNA	NULL
was	NULL
prepared	NULL
from	NULL
mouse	NULL
BM	NULL
and	NULL
spleen	NULL
using	NULL
the	NULL
guanidinium	NULL
thiocyanate	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Denatured	NULL
RNA	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
was	NULL
hybridized	NULL
with	NULL
the	NULL
human	NULL
RARa	NULL
probe	NULL
IT	NULL
(	NULL
5	NULL
)	NULL
following	NULL
standard	NULL
procedures	NULL
(	NULL
33	NULL
)	NULL
.	NULL

RT-PCR	NULL
was	NULL
also	NULL
used	NULL
to	NULL
analyze	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
(	NULL
34	NULL
)	NULL
using	NULL
the	NULL
primers	NULL
MA4-R7	NULL
for	NULL
the	NULL
first	NULL
round	NULL
of	NULL
amplification	NULL
and	NULL
M2-Rj	NULL
for	NULL
the	NULL
nested	NULL
round	NULL
,	NULL
or	NULL
RAR	NULL
(	NULL
d	NULL
)	NULL
-Cat	NULL
(	NULL
b	NULL
)	NULL
for	NULL
first	NULL
and	NULL
F1-B1	NULL
for	NULL
nested	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Primers	NULL
:	NULL
M4	NULL
,	NULL
CTGGAGGCTGTGGACGCGCCG-GTA	NULL
;	NULL
R7	NULL
,	NULL
TCTTTCTGGATGCTGCGGCGGAA	NULL
;	NULL
M2	NULL
,	NULL
AGTG-TACGCCTTCTCCATCAAAG	NULL
;	NULL
RJ	NULL
,	NULL
CTTGCAGCCCTCA-CAGGCGCT	NULL
;	NULL
RAR	NULL
(	NULL
d	NULL
)	NULL
,	NULL
CAGCTCCAACAGAAGCAGC	NULL
;	NULL
Cat	NULL
(	NULL
b	NULL
)	NULL
,	NULL
CAATGAGCTGCTGTCAGCA	NULL
;	NULL
F1	NULL
,	NULL
TCTCTGCCITT-TCTACCGACC	NULL
;	NULL
B1	NULL
,	NULL
CTGGATCTGAAGATACGCC	NULL
.	NULL

Immunofluorescence	NULL
.	NULL

BM	NULL
and	NULL
spleen	NULL
cells	NULL
were	NULL
fixed	NULL
with	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
for	NULL
10	NULL
min	NULL
and	NULL
permeabilized	NULL
with	NULL
methanol	NULL
at	NULL
-20°C	NULL
for	NULL
7	NULL
min	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
subsequently	NULL
incubated	NULL
with	NULL
a	NULL
primary	NULL
«	NULL
-PML	NULL
antibody	NULL
[	NULL
kindly	NULL
provided	NULL
by	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
5303	NULL
P.	NULL
Freemont	NULL
,	NULL
Imperial	NULL
Cancer	NULL
Research	NULL
Fund	NULL
(	NULL
ICRF	NULL
)	NULL
,	NULL
Lon-don	NULL
]	NULL
.	NULL

Hematology	NULL
,	NULL
Histopathology	NULL
,	NULL
and	NULL
Immunohistochemistry	NULL
.	NULL

White	NULL
blood	NULL
cell	NULL
(	NULL
WBC	NULL
)	NULL
,	NULL
hemoglobin	NULL
,	NULL
and	NULL
platelet	NULL
counts	NULL
in	NULL
peripheral	NULL
blood	NULL
(	NULL
PB	NULL
)	NULL
were	NULL
determined	NULL
using	NULL
an	NULL
automated	NULL
counter	NULL
(	NULL
Technicon-H2	NULL
)	NULL
.	NULL

Differential	NULL
counts	NULL
of	NULL
PB	NULL
and	NULL
BM	NULL
were	NULL
performed	NULL
microscopically	NULL
on	NULL
Wright-Giemsa	NULL
stained	NULL
smears	NULL
.	NULL

A	NULL
minimum	NULL
of	NULL
100	NULL
cells	NULL
for	NULL
PB	NULL
or	NULL
300-500	NULL
cells	NULL
for	NULL
BM	NULL
were	NULL
examined	NULL
and	NULL
reported	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
each	NULL
kind	NULL
of	NULL
cell	NULL
in	NULL
the	NULL
nucleated	NULL
cells	NULL
.	NULL

Sections	NULL
(	NULL
4	NULL
um	NULL
)	NULL
from	NULL
various	NULL
hematopoietic	NULL
organs	NULL
,	NULL
including	NULL
BM	NULL
,	NULL
spleen	NULL
,	NULL
liver	NULL
,	NULL
thymus	NULL
,	NULL
and	NULL
lymph	NULL
nodes	NULL
,	NULL
were	NULL
stained	NULL
with	NULL
hematoxylin	NULL
and	NULL
eosin	NULL
and	NULL
examined	NULL
.	NULL

Myelo-peroxidase	NULL
(	NULL
MPO	NULL
;	NULL
Dako	NULL
)	NULL
,	NULL
B220	NULL
(	NULL
CD4SR	NULL
)	NULL
,	NULL
and	NULL
CD3	NULL
antibodies	NULL
(	NULL
PharMingen	NULL
)	NULL
were	NULL
used	NULL
for	NULL
the	NULL
immunohistochemistry	NULL
staining	NULL
on	NULL
BM	NULL
and	NULL
spleen	NULL
sections	NULL
as	NULL
described	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Flow	NULL
Cytometry	NULL
.	NULL

PB	NULL
,	NULL
BM	NULL
,	NULL
and	NULL
spleen	NULL
cells	NULL
(	NULL
10°	NULL
cells	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
Mac-1	NULL
(	NULL
CD11b	NULL
)	NULL
antibody	NULL
and	NULL
Gr-1	NULL
(	NULL
myeloid	NULL
differentiation	NULL
antigen	NULL
)	NULL
or	NULL
c-Kit	NULL
(	NULL
CD117	NULL
)	NULL
antibodies	NULL
after	NULL
being	NULL
blocked	NULL
with	NULL
an	NULL
unlabeled	NULL
FeyR	NULL
(	NULL
CD16/32	NULL
)	NULL
antibody	NULL
.	NULL

All	NULL
antibodies	NULL
were	NULL
obtained	NULL
from	NULL
PharMingen	NULL
.	NULL

At	NULL
least	NULL
2	NULL
X	NULL
10	NULL
events	NULL
were	NULL
analyzed	NULL
from	NULL
each	NULL
sample	NULL
on	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Clonogenic	NULL
Assays	NULL
.	NULL

BM	NULL
and	NULL
spleen	NULL
cells	NULL
were	NULL
seeded	NULL
in	NULL
0.9	NULL
%	NULL
methylcellulose	NULL
medium	NULL
containing	NULL
30	NULL
%	NULL
FBS	NULL
,	NULL
1	NULL
%	NULL
BSA	NULL
,	NULL
10~-*	NULL
M	NULL
2-mercaptoethanol	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
2	NULL
%	NULL
pokeweed	NULL
mitogen-stimulated	NULL
spleen	NULL
cell	NULL
conditioned	NULL
media	NULL
,	NULL
and	NULL
3	NULL
units/ml	NULL
erythropoietin	NULL
(	NULL
StemCell	NULL
Technologies	NULL
,	NULL
Vancouver	NULL
)	NULL
.	NULL

CFU-E	NULL
were	NULL
scored	NULL
on	NULL
day	NULL
2	NULL
,	NULL
and	NULL
BFU-E	NULL
,	NULL
CFU-GM	NULL
,	NULL
and	NULL
CFU-GEMM	NULL
were	NULL
scored	NULL
on	NULL
day	NULL
10	NULL
.	NULL

RA	NULL
Differentiation	NULL
Assays	NULL
.	NULL

Mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
BM	NULL
and	NULL
spleen	NULL
suspensions	NULL
by	NULL
Ficoll-hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Cultures	NULL
were	NULL
established	NULL
at	NULL
a	NULL
cell	NULL
concentration	NULL
of	NULL
10°	NULL
per	NULL
ml	NULL
in	NULL
a-MEM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
antibiotics	NULL
in	NULL
a	NULL
24-well-plate	NULL
with	NULL
or	NULL
without	NULL
RA	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
10-8	NULL
M.	NULL
RA-sensitive	NULL
NB4	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
differentiation	NULL
.	NULL

At	NULL
days	NULL
0	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
from	NULL
culture	NULL
for	NULL
quantitative	NULL
evaluation	NULL
of	NULL
differentiation	NULL
induction	NULL
by	NULL
applying	NULL
the	NULL
nitro	NULL
blue	NULL
tetrazolium	NULL
(	NULL
NBT	NULL
)	NULL
test	NULL
(	NULL
see	NULL
below	NULL
)	NULL
,	NULL
and	NULL
morphological	NULL
differential	NULL
count	NULL
.	NULL

The	NULL
NBT-positive	NULL
percentage	NULL
was	NULL
obtained	NULL
by	NULL
microscopic	NULL
scoring	NULL
of	NULL
100	NULL
cells	NULL
.	NULL

RESULTS	NULL
Production	NULL
of	NULL
PML	NULL
/RARa	NULL
Transgenic	NULL
Mice	NULL
.	NULL

In	NULL
our	NULL
attempt	NULL
to	NULL
generate	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
,	NULL
we	NULL
noticed	NULL
that	NULL
transgene	NULL
expression	NULL
driven	NULL
by	NULL
housekeeping	NULL
promoters	NULL
such	NULL
as	NULL
B-actin	NULL
resulted	NULL
in	NULL
fetal	NULL
lethality	NULL
.	NULL

We	NULL
presume	NULL
this	NULL
is	NULL
due	NULL
to	NULL
high	NULL
expression	NULL
of	NULL
a	NULL
mutant	NULL
RARa	NULL
interfering	NULL
with	NULL
the	NULL
RAR/RXR	NULL
pathway	NULL
.	NULL

To	NULL
avoid	NULL
the	NULL
potential	NULL
toxicity	NULL
of	NULL
the	NULL
fusion	NULL
proteins	NULL
for	NULL
the	NULL
developing	NULL
embryo	NULL
,	NULL
we	NULL
decided	NULL
to	NULL
generate	NULL
transgenic	NULL
mice	NULL
in	NULL
which	NULL
the	NULL
APL-specific	NULL
fusion	NULL
genes	NULL
(	NULL
cDNAs	NULL
)	NULL
are	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
regulatory	NULL
elements	NULL
of	NULL
the	NULL
myeloid	NULL
/promyelocytic	NULL
specific	NULL
cathepsin-G	NULL
gene	NULL
(	NULL
36	NULL
)	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
we	NULL
generated	NULL
a	NULL
cathepsin-G	NULL
minigene	NULL
expression	NULL
vector	NULL
by	NULL
cloning	NULL
and	NULL
modifying	NULL
a	NULL
6.7-kb	NULL
BamHI-BamHI	NULL
genomic	NULL
fragment	NULL
of	NULL
the	NULL
hCG	NULL
gene	NULL
that	NULL
is	NULL
larger	NULL
than	NULL
a	NULL
fragment	NULL
which	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
retain	NULL
promyelocytic	NULL
specificity	NULL
in	NULL
transgenic	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
and	NULL
ref	NULL
.	NULL

36	NULL
)	NULL
.	NULL

We	NULL
subcloned	NULL
the	NULL
PML/RARa	NULL
cDNA	NULL
as	NULL
well	NULL
as	NULL
a	NULL
Lac-Z	NULL
cDNA	NULL
into	NULL
this	NULL
vector	NULL
using	NULL
the	NULL
unique	NULL
Se/I	NULL
restriction	NULL
enzyme	NULL
cloning	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
hCG-Lac-Z	NULL
construct	NULL
was	NULL
injected	NULL
into	NULL
mouse	NULL
eggs	NULL
,	NULL
and	NULL
embryos	NULL
were	NULL
killed	NULL
at	NULL
12.5	NULL
,	NULL
14.5	NULL
,	NULL
and	NULL
16.5	NULL
days	NULL
post	NULL
coitus	NULL
and	NULL
stained	NULL
for	NULL
B-galactosidase	NULL
activity	NULL
to	NULL
test	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
hCG	NULL
expression	NULL
vector	NULL
.	NULL

Positive	NULL
staining	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
liver	NULL
(	NULL
12.5	NULL
and	NULL
14.5	NULL
days	NULL
post	NULL
coitus	NULL
)	NULL
and	NULL
in	NULL
the	NULL
BM	NULL
(	NULL
16.5	NULL
days	NULL
post	NULL
coitus	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
observed	NULL
variable	NULL
staining	NULL
in	NULL
other	NULL
organs	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
minigene	NULL
is	NULL
susceptible	NULL
to	NULL
position-dependent	NULL
effects	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

5304	NULL
Medical	NULL
Sciences	NULL
:	NULL
He	NULL
et	NULL
al	NULL
.	NULL

The	NULL
progeny	NULL
obtained	NULL
from	NULL
injection	NULL
of	NULL
the	NULL
hCG-PML/	NULL
RARa	NULL
was	NULL
analyzed	NULL
by	NULL
Southern	NULL
blotting	NULL
on	NULL
DNA	NULL
obtained	NULL
from	NULL
mouse	NULL
tails	NULL
and	NULL
digested	NULL
with	NULL
EcoRI	NULL
,	NULL
using	NULL
a	NULL
human-specific	NULL
cathepsin-G	NULL
probe	NULL
(	NULL
CT	NULL
)	NULL
which	NULL
does	NULL
not	NULL
cross-react	NULL
with	NULL
the	NULL
endogenous	NULL
mouse	NULL
cathepsin-G	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Using	NULL
this	NULL
screening	NULL
method	NULL
,	NULL
we	NULL
identified	NULL
four	NULL
independent	NULL
transgenic	NULL
founders	NULL
carrying	NULL
the	NULL
hCG-PML/RARa	NULL
transgene	NULL
.	NULL

Southern	NULL
blot	NULL
analysis	NULL
of	NULL
offspring	NULL
from	NULL
the	NULL
various	NULL
founders	NULL
with	NULL
two	NULL
distinct	NULL
probes	NULL
(	NULL
HS1	NULL
and	NULL
CT	NULL
)	NULL
and	NULL
using	NULL
two	NULL
different	NULL
restriction	NULL
enzyme	NULL
digestions	NULL
(	NULL
EcoRI	NULL
and	NULL
HindIII	NULL
)	NULL
showed	NULL
integration	NULL
of	NULL
between	NULL
2	NULL
and	NULL
32	NULL
intact	NULL
copies	NULL
of	NULL
the	NULL
transgene	NULL
in	NULL
a	NULL
head-to-tail	NULL
and/or	NULL
tail-to-tail	NULL
arrangement	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
4	NULL
and	NULL
B	NULL
and	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
PML	NULL
/RARa	NULL
Expression	NULL
Driven	NULL
by	NULL
the	NULL
hCG	NULL
Mini-gene	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
PML	NULL
/RARa	NULL
fusion	NULL
gene	NULL
was	NULL
initially	NULL
studied	NULL
by	NULL
RT-PCR	NULL
analysis	NULL
on	NULL
RNA	NULL
extracted	NULL
from	NULL
BM	NULL
and	NULL
spleen	NULL
of	NULL
the	NULL
progeny	NULL
of	NULL
the	NULL
four	NULL
founders	NULL
following	NULL
the	NULL
nested	NULL
RT-PCR	NULL
approach	NULL
that	NULL
is	NULL
presently	NULL
used	NULL
in	NULL
our	NULL
lab	NULL
to	NULL
detect	NULL
minimal	NULL
residual	NULL
disease	NULL
in	NULL
APL	NULL
patients	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
and	NULL
C	NULL
,	NULL
and	NULL
ref	NULL
.	NULL

34	NULL
)	NULL
.	NULL

Progeny	NULL
from	NULL
founders	NULL
6173	NULL
,	NULL
6179	NULL
,	NULL
and	NULL
6380	NULL
were	NULL
found	NULL
to	NULL
be	NULL
positive	NULL
.	NULL

Lines	NULL
6179	NULL
and	NULL
6380	NULL
were	NULL
further	NULL
expanded	NULL
and	NULL
characterized	NULL
.	NULL

To	NULL
make	NULL
sure	NULL
that	NULL
the	NULL
hCG/PML/RARa	NULL
fusion	NULL
cDNA	NULL
was	NULL
not	NULL
contaminated	NULL
by	NULL
genomic	NULL
transgene	NULL
sequences	NULL
,	NULL
we	NULL
took	NULL
several	NULL
precautions	NULL
.	NULL

(	NULL
¢	NULL
)	NULL
We	NULL
performed	NULL
the	NULL
RT-PCR	NULL
in	NULL
parallel	NULL
on	NULL
RNA	NULL
samples	NULL
with	NULL
and	NULL
without	NULL
RT	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

(	NULL
#	NULL
)	NULL
We	NULL
also	NULL
used	NULL
two	NULL
pairs	NULL
of	NULL
oligonucle-otides	NULL
[	NULL
Rd	NULL
and	NULL
Cat	NULL
(	NULL
b	NULL
)	NULL
,	NULL
and	NULL
F1	NULL
and	NULL
B1	NULL
]	NULL
that	NULL
span	NULL
cathepsin-G	NULL
intron	NULL
1	NULL
,	NULL
thus	NULL
allowing	NULL
us	NULL
to	NULL
distinguish	NULL
the	NULL
unprocessed	NULL
gene	NULL
from	NULL
the	NULL
processed	NULL
cDNA	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
and	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
was	NULL
subsequently	NULL
confirmed	NULL
by	NULL
Northern	NULL
blotting	NULL
and	NULL
immunofluorescence	NULL
analysis	NULL
on	NULL
BM	NULL
samples	NULL
obtained	NULL
from	NULL
mice	NULL
that	NULL
had	NULL
developed	NULL
overt	NULL
leukemia	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
confirmed	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
expected	NULL
hCG/	NULL
PML/RARa	NULL
fusion	NULL
transcript	NULL
of	NULL
approximately	NULL
4	NULL
kb	NULL
in	NULL
both	NULL
transgenic	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
)	NULL
.	NULL

Immunofluorescence	NULL
analysis	NULL
carried	NULL
out	NULL
with	NULL
a	NULL
PML	NULL
antibody	NULL
that	NULL
cross-reacts	NULL
with	NULL
both	NULL
human	NULL
and	NULL
murine	NULL
PML	NULL
protein	NULL
as	NULL
well	NULL
as	NULL
with	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
protein	NULL
revealed	NULL
a	NULL
striking	NULL
microspeckled	NULL
PML	NULL
distribution	NULL
in	NULL
the	NULL
BM	NULL
cells	NULL
from	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
classical	NULL
PML	NULL
accumulation	NULL
in	NULL
the	NULL
NBs	NULL
observed	NULL
in	NULL
the	NULL
cells	NULL
from	NULL
wild-type	NULL
control	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

1£	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
data	NULL
confirm	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
and	NULL
at	NULL
the	NULL
same	NULL
time	NULL
demonstrate	NULL
that	NULL
,	NULL
as	NULL
with	NULL
human	NULL
APL	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
PML/RAR	NULL
«	NULL
results	NULL
in	NULL
delocalization	NULL
of	NULL
PML	NULL
from	NULL
the	NULL
NBs	NULL
.	NULL

Aberrant	NULL
Hematopoiesis	NULL
and	NULL
Leukemia	NULL
in	NULL
PML/RARa	NULL
«	NULL
Transgenic	NULL
Mice	NULL
.	NULL

The	NULL
hematopoiesis	NULL
of	NULL
progeny	NULL
from	NULL
the	NULL
two	NULL
expressing	NULL
lines	NULL
was	NULL
systematically	NULL
analyzed	NULL
in	NULL
the	NULL
following	NULL
manner	NULL
over	NULL
a	NULL
14-month	NULL
follow-up	NULL
period	NULL
.	NULL

(	NULL
?	NULL
)	NULL

In	NULL
one	NULL
group	NULL
,	NULL
the	NULL
mice	NULL
were	NULL
bled	NULL
on	NULL
a	NULL
monthly	NULL
basis	NULL
,	NULL
together	NULL
with	NULL
appropriate	NULL
littermate	NULL
controls	NULL
of	NULL
the	NULL
same	NULL
sex	NULL
and	NULL
age	NULL
(	NULL
25	NULL
transgenic	NULL
mice	NULL
and	NULL
25	NULL
control	NULL
mice	NULL
per	NULL
line	NULL
)	NULL
.	NULL

Differential	NULL
counts	NULL
,	NULL
as	NULL
well	NULL
as	NULL
morphological	NULL
analysis	NULL
of	NULL
PB	NULL
cells	NULL
,	NULL
were	NULL
performed	NULL
on	NULL
each	NULL
sample	NULL
to	NULL
monitor	NULL
the	NULL
incidence	NULL
of	NULL
leukemia	NULL
.	NULL

(	NULL
#	NULL
)	NULL
In	NULL
the	NULL
second	NULL
group	NULL
,	NULL
4	NULL
transgenic	NULL
mice	NULL
and	NULL
4	NULL
controls	NULL
were	NULL
killed	NULL
every	NULL
2	NULL
months	NULL
,	NULL
at	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
etc	NULL
.	NULL

,	NULL
months	NULL
of	NULL
age	NULL
,	NULL
for	NULL
gross	NULL
and	NULL
microscopic	NULL
examination	NULL
of	NULL
all	NULL
organs	NULL
and	NULL
in	NULL
particular	NULL
PB	NULL
,	NULL
BM	NULL
,	NULL
spleen	NULL
,	NULL
lymph	NULL
nodes	NULL
,	NULL
and	NULL
thymus	NULL
.	NULL

These	NULL
organs	NULL
and	NULL
their	NULL
cell	NULL
populations	NULL
were	NULL
analyzed	NULL
morphologically	NULL
on	NULL
touch	NULL
preparation	NULL
,	NULL
smears	NULL
,	NULL
and	NULL
cytospin	NULL
preparations	NULL
stained	NULL
with	NULL
Wright-Giemsa	NULL
.	NULL

This	NULL
analysis	NULL
revealed	NULL
a	NULL
profound	NULL
disturbance	NULL
of	NULL
myeloid	NULL
hematopoiesis	NULL
in	NULL
both	NULL
transgenic	NULL
lines	NULL
that	NULL
can	NULL
be	NULL
divided	NULL
into	NULL
two	NULL
distinct	NULL
phases	NULL
.	NULL

(	NULL
?	NULL
)	NULL

The	NULL
first	NULL
phase	NULL
is	NULL
a	NULL
long	NULL
asymptomatic	NULL
preleukemia	NULL
phase	NULL
in	NULL
which	NULL
the	NULL
transgenic	NULL
mice	NULL
develop	NULL
what	NULL
in	NULL
human	NULL
would	NULL
be	NULL
described	NULL
as	NULL
a	NULL
myeloproliferative	NULL
disorder	NULL
.	NULL

In	NULL
this	NULL
phase	NULL
,	NULL
myeloid	NULL
precursors	NULL
,	NULL
including	NULL
promyelocytes	NULL
(	NULL
up	NULL
to	NULL
10	NULL
%	NULL
;	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
progressively	NULL
accumulate	NULL
in	NULL
the	NULL
BM	NULL
,	NULL
and	NULL
infiltrate	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
HS1	NULL
M2	NULL
#	NULL
<	NULL
p	NULL
;	NULL
Fi	NULL
»	NULL
+	NULL
B1	NULL
CT	NULL
Bop	NULL
2	NULL
£	NULL
ﬂ	NULL
Peirg	NULL
-	NULL
Pesso	NULL
g	NULL
;	NULL
£251	NULL
<	NULL
‘	NULL
9-	NULL
-	NULL
28	NULL
£8	NULL
m	NULL
PML/RAR	NULL
TRANS	NULL
-6.2Kb	NULL
PMLRAR	NULL
:	NULL
(	NULL
475	NULL
bp	NULL
)	NULL
C	NULL
ee	NULL
``	NULL
T	NULL
``	NULL
T	NULL
eT	NULL
TI	NULL
D	NULL
E	NULL
PMLRARC	NULL
I	NULL
>	NULL
i	NULL
o	NULL
p	NULL
>	NULL
RARC	NULL
3	NULL
t	NULL
>	NULL
bap	NULL
TRANS	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Structure	NULL
,	NULL
integration	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
hCG-PML/	NULL
RARa	NULL
transgene	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Structure	NULL
of	NULL
the	NULL
hCG	NULL
minigene	NULL
expression	NULL
vector	NULL
(	NULL
Upper	NULL
)	NULL
and	NULL
the	NULL
hCG-PML/RARa	NULL
transgene	NULL
fragment	NULL
used	NULL
for	NULL
injection	NULL
(	NULL
Lower	NULL
)	NULL
.	NULL

The	NULL
exons	NULL
of	NULL
hCG	NULL
gene	NULL
are	NULL
designated	NULL
by	NULL
solid	NULL
boxes	NULL
.	NULL

The	NULL
promoter	NULL
and	NULL
the	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
(	NULL
hCG-PR	NULL
+	NULL
5	NULL
'	NULL
FL	NULL
)	NULL
as	NULL
well	NULL
as	NULL
the	NULL
3	NULL
'	NULL
flanking	NULL
region	NULL
(	NULL
3	NULL
'	NULL
FL	NULL
)	NULL
of	NULL
the	NULL
hCG	NULL
gene	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
PML/RARa	NULL
cDNA	NULL
was	NULL
cloned	NULL
into	NULL
hCG	NULL
exon	NULL
1	NULL
.	NULL

Restriction	NULL
endonuclease	NULL
sites	NULL
used	NULL
in	NULL
construction	NULL
and	NULL
Southern	NULL
blotting	NULL
are	NULL
as	NULL
follows	NULL
:	NULL
N	NULL
,	NULL
NofI	NULL
;	NULL
B	NULL
,	NULL
BamHI	NULL
;	NULL
E	NULL
,	NULL
EcoRI	NULL
;	NULL
C	NULL
,	NULL
Clel	NULL
;	NULL
S	NULL
,	NULL
Sall	NULL
;	NULL
P	NULL
,	NULL
Pll	NULL
;	NULL
X	NULL
,	NULL
Xbal	NULL
;	NULL
H	NULL
,	NULL
HindIII	NULL
.	NULL

The	NULL
location	NULL
of	NULL
probes	NULL
for	NULL
Southern	NULL
blotting	NULL
and	NULL
primers	NULL
for	NULL
RT-PCR	NULL
are	NULL
shown	NULL
underneath	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
injected	NULL
fragment	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Southern	NULL
blot	NULL
of	NULL
mouse	NULL
genomic	NULL
tail	NULL
DNA	NULL
from	NULL
the	NULL
four	NULL
transgenic	NULL
founders	NULL
and	NULL
one	NULL
control	NULL
digested	NULL
with	NULL
EcoRI	NULL
and	NULL
hybridized	NULL
with	NULL
probe	NULL
CT	NULL
reveals	NULL
the	NULL
expected	NULL
band	NULL
of	NULL
6.2	NULL
kb	NULL
.	NULL

PML	NULL
probe	NULL
A	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
was	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
probe	NULL
to	NULL
normalize	NULL
DNA	NULL
loading	NULL
.	NULL

Lanes	NULL
:	NULL
6173	NULL
,	NULL
6179	NULL
,	NULL
6378	NULL
,	NULL
and	NULL
6380	NULL
,	NULL
four	NULL
founders	NULL
;	NULL
6177	NULL
,	NULL
nontransgenic	NULL
mouse	NULL
.	NULL

(	NULL
C	NULL
)	NULL
RT-PCR	NULL
analysis	NULL
of	NULL
PML/RARa	NULL
fusion	NULL
mRNA	NULL
expression	NULL
in	NULL
BM	NULL
cells	NULL
from	NULL
progeny	NULL
from	NULL
founders	NULL
6179	NULL
(	NULL
P6179	NULL
)	NULL
and	NULL
6380	NULL
(	NULL
P6380	NULL
)	NULL
.	NULL

Representative	NULL
result	NULL
of	NULL
nested	NULL
PCR	NULL
is	NULL
shown	NULL
.	NULL

Negative	NULL
control	NULL
,	NULL
RNA	NULL
from	NULL
a	NULL
nontransgenic	NULL
mouse	NULL
;	NULL
positive	NULL
control	NULL
,	NULL
RNA	NULL
from	NULL
an	NULL
APL	NULL
patient	NULL
with	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
;	NULL
M	NULL
,	NULL
pGEM	NULL
DNA	NULL
markers	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Northern	NULL
blot	NULL
on	NULL
total	NULL
RNA	NULL
from	NULL
leukemic	NULL
progeny	NULL
from	NULL
lines	NULL
6179	NULL
(	NULL
LP6179	NULL
)	NULL
and	NULL
6380	NULL
(	NULL
LP6380	NULL
)	NULL
hybridized	NULL
with	NULL
the	NULL
human	NULL
RARa	NULL
probe	NULL
IT	NULL
(	NULL
5	NULL
)	NULL
.	NULL

WT	NULL
,	NULL
nontransgenic	NULL
mouse	NULL
;	NULL
hAPL	NULL
,	NULL
APL	NULL
patient	NULL
with	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
[	NULL
PML	NULL
of	NULL
ber1	NULL
type	NULL
(	NULL
ref	NULL
.	NULL

12	NULL
)	NULL
]	NULL
.	NULL

Expected	NULL
4.0-kb	NULL
transcript	NULL
for	NULL
hCG-PML/RARa	NULL
transgene	NULL
{	NULL
left	NULL
solid	NULL
arrowhead	NULL
)	NULL
and	NULL
4.4-kb	NULL
transcript	NULL
for	NULL
human	NULL
PML/RARa	NULL
chimeric	NULL
mRNA	NULL
(	NULL
right	NULL
solid	NULL
arrowhead	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

Open	NULL
arrowheads	NULL
indicate	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
two	NULL
RARa	NULL
transcripts	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
288	NULL
and	NULL
the	NULL
188	NULL
ribosomal	NULL
RNA	NULL
transcripts	NULL
are	NULL
also	NULL
indicated	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Immunofluorescence	NULL
staining	NULL
of	NULL
BM	NULL
cells	NULL
from	NULL
control	NULL
mice	NULL
(	NULL
WT	NULL
)	NULL
and	NULL
leukemic	NULL
hCG-PML/RARa	NULL
transgenic	NULL
mice	NULL
.	NULL

PML	NULL
is	NULL
localized	NULL
within	NULL
the	NULL
NBs	NULL
in	NULL
nontransgenic	NULL
mouse	NULL
(	NULL
Upper	NULL
)	NULL
,	NULL
whereas	NULL
it	NULL
is	NULL
in	NULL
the	NULL
form	NULL
of	NULL
microspeckles	NULL
in	NULL
transgenic	NULL
mouse	NULL
(	NULL
Lower	NULL
)	NULL
.	NULL

4',6-Diamidino-2-phenylindole	NULL
(	NULL
DAPI	NULL
)	NULL
staining	NULL
was	NULL
used	NULL
to	NULL
visualize	NULL
cell	NULL
nuclei	NULL
.	NULL

Anti-PML	NULL
DAPI	NULL
LP6179	NULL
LP6380	NULL
the	NULL
spleen	NULL
,	NULL
the	NULL
lymph	NULL
nodes	NULL
,	NULL
and	NULL
the	NULL
thymus	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
partially	NULL
retain	NULL
the	NULL
ability	NULL
to	NULL
terminally	NULL
differentiate	NULL
toward	NULL
mature	NULL
granulocytes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

During	NULL
this	NULL
phase	NULL
,	NULL
the	NULL
PB	NULL
remains	NULL
essentially	NULL
normal	NULL
,	NULL
except	NULL
,	NULL
in	NULL
some	NULL
cases	NULL
,	NULL
for	NULL
an	NULL
increased	NULL
granulocyte	NULL
/lymphocyte	NULL
ratio	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

By	NULL
12	NULL
months	NULL
of	NULL
age	NULL
,	NULL
all	NULL
the	NULL
mice	NULL
analyzed	NULL
had	NULL
developed	NULL
this	NULL
myeloproliferative	NULL
disorder	NULL
to	NULL
variable	NULL
degrees	NULL
of	NULL
severity	NULL
,	NULL
but	NULL
no	NULL
leukemia	NULL
was	NULL
observed	NULL
before	NULL
this	NULL
age	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
He	NULL
et	NULL
al	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
After	NULL
mice	NULL
reached	NULL
1	NULL
year	NULL
of	NULL
age	NULL
,	NULL
approximately	NULL
10	NULL
%	NULL
of	NULL
them	NULL
developed	NULL
overt	NULL
acute	NULL
leukemia	NULL
and	NULL
died	NULL
or	NULL
were	NULL
killed	NULL
.	NULL

Leukemia	NULL
was	NULL
diagnosed	NULL
according	NULL
to	NULL
the	NULL
postmortem	NULL
analysis	NULL
(	NULL
infiltrates	NULL
of	NULL
all	NULL
organs	NULL
analyzed	NULL
by	NULL
the	NULL
myeloid	NULL
blast	NULL
population	NULL
)	NULL
and	NULL
to	NULL
hematological	NULL
parameters	NULL
(	NULL
promyelocytes	NULL
and	NULL
blasts	NULL
percentage	NULL
in	NULL
the	NULL
BM	NULL
and	NULL
PB	NULL
)	NULL
.	NULL

This	NULL
leukemia	NULL
is	NULL
characterized	NULL
by	NULL
the	NULL
accumulation	NULL
of	NULL
promyelocytes	NULL
in	NULL
the	NULL
BM	NULL
,	NULL
PB	NULL
,	NULL
and	NULL
spleen	NULL
,	NULL
which	NULL
is	NULL
distinctive	NULL
of	NULL
APL	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
with	NULL
some	NULL
promyelocytes	NULL
showing	NULL
the	NULL
presence	NULL
of	NULL
pathognomonic	NULL
cytoplasmic	NULL
Auer	NULL
's	NULL
bodies	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
and	NULL
by	NULL
white	NULL
cell	NULL
counts	NULL
in	NULL
the	NULL
PB	NULL
(	NULL
WBC	NULL
)	NULL
higher	NULL
than	NULL
in	NULL
classical	NULL
human	NULL
APL	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
ref	NULL
.	NULL

1	NULL
)	NULL
.	NULL

As	NULL
in	NULL
the	NULL
myeloproliferative	NULL
phase	NULL
,	NULL
the	NULL
leukemic	NULL
cellular	NULL
population	NULL
partially	NULL
retains	NULL
the	NULL
ability	NULL
to	NULL
terminally	NULL
differentiate	NULL
toward	NULL
mature	NULL
granulocytes	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
remaining	NULL
90	NULL
%	NULL
of	NULL
the	NULL
mice	NULL
are	NULL
still	NULL
leukemia-free	NULL
after	NULL
a	NULL
14-month	NULL
follow-up	NULL
period	NULL
.	NULL

We	NULL
next	NULL
subjected	NULL
the	NULL
PB	NULL
,	NULL
BM	NULL
,	NULL
and	NULL
spleen	NULL
cells	NULL
from	NULL
leukemic	NULL
mice	NULL
to	NULL
a	NULL
flow	NULL
cytometric	NULL
analysis	NULL
with	NULL
antibodies	NULL
against	NULL
the	NULL
following	NULL
cell	NULL
surface	NULL
markers	NULL
:	NULL
c-Kit	NULL
(	NULL
totipotent	NULL
stem	NULL
cells	NULL
)	NULL
,	NULL
Gr-1	NULL
(	NULL
mature	NULL
granulocytes	NULL
and	NULL
monocytes	NULL
)	NULL
,	NULL
and	NULL
Mac-1	NULL
(	NULL
mature	NULL
monocytes	NULL
and	NULL
granulocytes	NULL
)	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

3	NULL
and	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

This	NULL
analysis	NULL
confirmed	NULL
the	NULL
myeloid	NULL
nature	NULL
of	NULL
the	NULL
leukemia	NULL
revealed	NULL
by	NULL
the	NULL
dramatic	NULL
accumulation	NULL
of	NULL
myeloid	NULL
cells	NULL
(	NULL
Mac-1-	NULL
and	NULL
Gr-l-positive	NULL
)	NULL
in	NULL
the	NULL
PB	NULL
and	NULL
spleen	NULL
of	NULL
the	NULL
leukemic	NULL
mice	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
aforementioned	NULL
observation	NULL
that	NULL
the	NULL
leukemic	NULL
cellular	NULL
population	NULL
partially	NULL
retains	NULL
the	NULL
ability	NULL
to	NULL
terminally	NULL
differentiate	NULL
.	NULL

It	NULL
is	NULL
also	NULL
interesting	NULL
to	NULL
note	NULL
the	NULL
marked	NULL
accumulation	NULL
of	NULL
c-Kit-positive	NULL
hematopoietic	NULL
precursors	NULL
in	NULL
the	NULL
spleen	NULL
of	NULL
the	NULL
leukemic	NULL
mice	NULL
.	NULL

In	NULL
vitro	NULL
cultures	NULL
of	NULL
BM	NULL
and	NULL
spleen	NULL
cells	NULL
from	NULL
leukemic	NULL
mice	NULL
and	NULL
control	NULL
littermates	NULL
were	NULL
also	NULL
performed	NULL
using	NULL
standard	NULL
conditions	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

CFU-E	NULL
were	NULL
scored	NULL
on	NULL
day	NULL
2	NULL
,	NULL
and	NULL
BFU-E	NULL
,	NULL
CFU-GM	NULL
,	NULL
and	NULL
CFU-GEMM	NULL
were	NULL
scored	NULL
on	NULL
day	NULL
10	NULL
.	NULL

The	NULL
clonogenic	NULL
capacity	NULL
of	NULL
hematopoietic	NULL
precursors	NULL
from	NULL
the	NULL
transgenic	NULL
mice	NULL
was	NULL
markedly	NULL
reduced	NULL
,	NULL
particularly	NULL
the	NULL
number	NULL
of	NULL
BFU-E	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
almost	NULL
complete	NULL
replacement	NULL
of	NULL
the	NULL
normal	NULL
hematopoietic	NULL
precursors	NULL
by	NULL
the	NULL
neoplastic	NULL
population	NULL
in	NULL
the	NULL
BM	NULL
and	NULL
spleen	NULL
of	NULL
the	NULL
leukemic	NULL
transgenic	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
the	NULL
number	NULL
of	NULL
clusters	NULL
(	NULL
small	NULL
colonies	NULL
,	NULL
containing	NULL
8-20	NULL
cells	NULL
)	NULL
,	NULL
characteristically	NULL
observed	NULL
in	NULL
BM	NULL
cultures	NULL
from	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
patients	NULL
(	NULL
37	NULL
)	NULL
,	NULL
is	NULL
clearly	NULL
increased	NULL
in	NULL
cultures	NULL
from	NULL
the	NULL
BM	NULL
,	NULL
and	NULL
dramatically	NULL
increased	NULL
in	NULL
the	NULL
cultures	NULL
from	NULL
the	NULL
spleen	NULL
of	NULL
leukemic	NULL
mice	NULL
.	NULL

Response	NULL
to	NULL
RA	NULL
of	NULL
Leukemic	NULL
Cells	NULL
from	NULL
PML	NULL
Transgenic	NULL
Mice	NULL
.	NULL

We	NULL
studied	NULL
the	NULL
capacity	NULL
of	NULL
the	NULL
blasts	NULL
from	NULL
the	NULL
leukemic	NULL
transgenic	NULL
mice	NULL
to	NULL
differentiate	NULL
upon	NULL
exposure	NULL
to	NULL
RA	NULL
at	NULL
the	NULL
same	NULL
concentration	NULL
(	NULL
10~°	NULL
M	NULL
)	NULL
used	NULL
to	NULL
trigger	NULL
the	NULL
differentiation	NULL
of	NULL
human	NULL
APL	NULL
blasts	NULL
(	NULL
38	NULL
)	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
BM	NULL
and	NULL
spleen	NULL
suspensions	NULL
and	NULL
cultured	NULL
for	NULL
a	NULL
week	NULL
with	NULL
or	NULL
without	NULL
RA	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

We	NULL
evaluated	NULL
the	NULL
induction	NULL
of	NULL
differentiation	NULL
with	NULL
the	NULL
help	NULL
of	NULL
the	NULL
NBT	NULL
test	NULL
,	NULL
and	NULL
scored	NULL
by	NULL
morphological	NULL
differential	NULL
count	NULL
for	NULL
the	NULL
percent	NULL
of	NULL
terminal	NULL
maturation	NULL
toward	NULL
the	NULL
granulocytic	NULL
compart-ment	NULL
.	NULL

In	NULL
control	NULL
mice	NULL
,	NULL
RA	NULL
increased	NULL
the	NULL
differentiation	NULL
of	NULL
the	NULL
hematopoietic	NULL
precursors	NULL
to	NULL
some	NULL
extent	NULL
,	NULL
whereas	NULL
it	NULL
markedly	NULL
increased	NULL
the	NULL
terminal	NULL
differentiation	NULL
(	NULL
up	NULL
to	NULL
60	NULL
%	NULL
)	NULL
of	NULL
the	NULL
leuke-	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
5305	NULL
WLT	NULL
.	NULL

PMLURAR	NULL
a	NULL
PB	NULL
Es	NULL
vﬂa	NULL
”	NULL
.	NULL

€	NULL
93	NULL
:	NULL
L	NULL
A	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Morphology	NULL
and	NULL
immunohistochemistry	NULL
of	NULL
PB	NULL
,	NULL
BM	NULL
,	NULL
and	NULL
spleen	NULL
(	NULL
SP	NULL
)	NULL
cells	NULL
from	NULL
wild-type	NULL
(	NULL
W.T	NULL
.	NULL
)	NULL

and	NULL
leukemic	NULL
hCG-PML/	NULL
RARa	NULL
transgenic	NULL
mice	NULL
.	NULL

The	NULL
smears	NULL
of	NULL
PB	NULL
or	NULL
imprints	NULL
of	NULL
BM	NULL
and	NULL
spleen	NULL
were	NULL
stained	NULL
with	NULL
Wright-Giemsa	NULL
stain	NULL
.	NULL

Magnified	NULL
detail	NULL
of	NULL
promyelocyte	NULL
morphology	NULL
is	NULL
shown	NULL
in	NULL
the	NULL
spleen	NULL
imprint	NULL
from	NULL
the	NULL
leukemic	NULL
hCG-PML/RARa	NULL
mouse	NULL
.	NULL

Auer	NULL
's	NULL
bodies	NULL
are	NULL
visible	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
the	NULL
leukemic	NULL
promyelocytes	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
arrows	NULL
.	NULL

The	NULL
serial	NULL
spleen	NULL
sections	NULL
shown	NULL
in	NULL
the	NULL
bottom	NULL
panel	NULL
were	NULL
immuno-histochemically	NULL
stained	NULL
with	NULL
MPO	NULL
(	NULL
myeloid	NULL
precursors	NULL
and	NULL
mature	NULL
granulocytes	NULL
)	NULL
and	NULL
B220	NULL
(	NULL
pan-B	NULL
cells	NULL
,	NULL
Inset	NULL
)	NULL
antibodies	NULL
.	NULL

(	NULL
X400	NULL
for	NULL
PB	NULL
;	NULL
x1,000	NULL
for	NULL
BM	NULL
and	NULL
spleen	NULL
;	NULL
X128	NULL
for	NULL
immunohistochemical	NULL
staining	NULL
.	NULL
)	NULL

Note	NULL
that	NULL
in	NULL
the	NULL
leukemic	NULL
mice	NULL
,	NULL
the	NULL
number	NULL
of	NULL
WBC	NULL
in	NULL
PB	NULL
is	NULL
much	NULL
increased	NULL
;	NULL
the	NULL
normal	NULL
BM	NULL
components	NULL
,	NULL
including	NULL
erythrocytes	NULL
and	NULL
megakaryocytes	NULL
,	NULL
are	NULL
replaced	NULL
by	NULL
myeloid	NULL
cells	NULL
at	NULL
various	NULL
maturation	NULL
stages	NULL
;	NULL
the	NULL
spleen	NULL
is	NULL
heavily	NULL
infiltrated	NULL
by	NULL
MPO-positive	NULL
cells	NULL
.	NULL

mic	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
,	NULL
as	NULL
with	NULL
human	NULL
APL	NULL
,	NULL
the	NULL
leukemic	NULL
blasts	NULL
accumulating	NULL
in	NULL
the	NULL
PML/RARa	NULL
«	NULL
transgenic	NULL
mice	NULL
are	NULL
sensitive	NULL
to	NULL
the	NULL
differentiating	NULL
action	NULL
of	NULL
RA	NULL
and	NULL
that	NULL
the	NULL
maturation	NULL
block	NULL
at	NULL
the	NULL
promyelocytic	NULL
stage	NULL
can	NULL
be	NULL
reverted	NULL
by	NULL
this	NULL
agent	NULL
.	NULL

DISCUSSION	NULL
In	NULL
APL	NULL
,	NULL
RARa	NULL
variably	NULL
fuses	NULL
to	NULL
PML	NULL
,	NULL
PLZF	NULL
,	NULL
NPM	NULL
,	NULL
and	NULL
NUMA	NULL
(	NULL
X	NULL
proteins	NULL
)	NULL
.	NULL

In	NULL
terms	NULL
of	NULL
structure	NULL
,	NULL
what	NULL
the	NULL
various	NULL
RARa	NULL
«	NULL
partners	NULL
contribute	NULL
to	NULL
the	NULL
chimeric	NULL
products	NULL
is	NULL
dramatically	NULL
dif-ferent	NULL
;	NULL
and	NULL
at	NULL
the	NULL
first	NULL
glance	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
only	NULL
common	NULL
feature	NULL
among	NULL
the	NULL
fusion	NULL
proteins	NULL
is	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
B	NULL
to	NULL
F	NULL
Table	NULL
1	NULL
.	NULL

Automated	NULL
and	NULL
differential	NULL
counts	NULL
of	NULL
PB	NULL
and	NULL
BM	NULL
from	NULL
transgenic	NULL
and	NULL
wild-type	NULL
mice	NULL
PB	NULL
BM	NULL
Hb	NULL
,	NULL
Plt	NULL
,	NULL
WBC	NULL
,	NULL
Pro+blasts	NULL
,	NULL
Mye+meta	NULL
,	NULL
Pro+blasts	NULL
,	NULL
Mice	NULL
g/dl	NULL
10°/liter	NULL
10°/liter	NULL
M/L	NULL
M/L	NULL
M/E	NULL
Poly	NULL
,	NULL
%	NULL
%	NULL
%	NULL
Wild	NULL
type	NULL
15.1	NULL
+	NULL
#	NULL
0.9	NULL
1,278	NULL
+201	NULL
11.0	NULL
_	NULL
0.23	NULL
+	NULL
0.1	NULL
3.54	NULL
+	NULL
2.6	NULL
1.92	NULL
%	NULL
0.8	NULL
34.1	NULL
9.9	NULL
#	NULL
5.2	NULL
3.0	NULL
+1.0	NULL
Preleukemia	NULL
17.7	NULL
+	NULL
2.1	NULL
990	NULL
+	NULL
299	NULL
9.1	NULL
+	NULL
3.0	NULL
0.82	NULL
+	NULL
0.7	NULL
11.38	NULL
#	NULL
1.7	NULL
715	NULL
#	NULL
5.2	NULL
43.6	NULL
+6.2	NULL
24.9+10.0	NULL
7.9	NULL
+	NULL
0.9	NULL
Leukemia	NULL
10.0	NULL
+	NULL
5.7	NULL
280	NULL
+	NULL
100	NULL
1484	NULL
+	NULL
114.4	NULL
7.75	NULL
+	NULL
#	NULL
5.7	NULL
68	NULL
+4.9	NULL
38.2	NULL
+	NULL
14.5	NULL
47.8	NULL
+	NULL
16.3	NULL
35.2	NULL
+234	NULL
12.0	NULL
+	NULL
8.8	NULL
46.3	NULL
+	NULL
15.0	NULL
Preleukemia	NULL
,	NULL
transgenic	NULL
mice	NULL
showing	NULL
some	NULL
abnormal	NULL
signs	NULL
in	NULL
PB	NULL
,	NULL
BM	NULL
,	NULL
or	NULL
spleen	NULL
but	NULL
not	NULL
having	NULL
reached	NULL
leukemic	NULL
criteria	NULL
;	NULL
Hb	NULL
,	NULL
hemoglobin	NULL
;	NULL
Pit	NULL
,	NULL
platelet	NULL
;	NULL
M/L	NULL
,	NULL
ratio	NULL
of	NULL
various	NULL
differentiation	NULL
stage	NULL
granulocytes	NULL
(	NULL
M	NULL
)	NULL
to	NULL
lymphocytes	NULL
(	NULL
L	NULL
)	NULL
;	NULL
M/E	NULL
,	NULL
ratio	NULL
of	NULL
various	NULL
differentiation	NULL
stage	NULL
granulocytes	NULL
(	NULL
M	NULL
)	NULL
to	NULL
nucleated	NULL
erythrocytes	NULL
(	NULL
E	NULL
)	NULL
;	NULL
Poly	NULL
,	NULL
polymorphonuclear	NULL
granulocytes	NULL
;	NULL
Mye+meta	NULL
,	NULL
myelocytes	NULL
plus	NULL
metamyelocytes	NULL
;	NULL
Pro+blasts	NULL
,	NULL
promyelocytes	NULL
plus	NULL
blasts	NULL
.	NULL

The	NULL
number	NULL
of	NULL
mice	NULL
used	NULL
in	NULL
this	NULL
analysis	NULL
is	NULL
as	NULL
follows	NULL
:	NULL
4	NULL
leukemia	NULL
,	NULL
4	NULL
preleukemia	NULL
,	NULL
5	NULL
wild-type	NULL
for	NULL
BM	NULL
,	NULL
and	NULL
10	NULL
wild-type	NULL
for	NULL
PB	NULL
.	NULL

5306	NULL
Medical	NULL
Sciences	NULL
:	NULL
He	NULL
et	NULL
al	NULL
.	NULL

PB	NULL
BM	NULL
PML/RARe	NULL
:	NULL
W.T	NULL
.	NULL

PML/RARa	NULL
250	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
Spleen	NULL
W.T	NULL
.	NULL

PML/RARa	NULL
250	NULL
SSC	NULL
o	NULL
250	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
PB	NULL
,	NULL
BM	NULL
,	NULL
and	NULL
spleen	NULL
cells	NULL
°	NULL
o	NULL
Fe	NULL
so	NULL
.	NULL

100	NULL
150	NULL
200	NULL
250	NULL
6	NULL
So	NULL
ibo	NULL
teo	NULL
abo	NULL
sen	NULL
-	NULL
6.	NULL
so	NULL
100	NULL
150	NULL
abo	NULL
260	NULL
FSC	NULL
from	NULL
leukemic	NULL
hCG-PML/	NULL
RARa	NULL
transgenic	NULL
and	NULL
wild-type	NULL
mice	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
analyzed	NULL
o	NULL
.	NULL

o	NULL
5	NULL
36	NULL
100	NULL
teo	NULL
2b	NULL
cso	NULL
do	NULL
100	NULL
150	NULL
abo	NULL
250	NULL
3	NULL
E	NULL
E	NULL
&	NULL
1.3	NULL
%	NULL
3.7	NULL
%	NULL
.	NULL

3	NULL
.	NULL

4.7	NULL
%	NULL
11.1	NULL
%	NULL
ee	NULL
|	NULL
A	NULL
\_	NULL
|	NULL
Ae	NULL
.	NULL
]	NULL

-	NULL
e	NULL
3	NULL
3	NULL
with	NULL
antibodies	NULL
against	NULL
the	NULL
cell	NULL
0.8	NULL
%	NULL
po	NULL
200	NULL
%	NULL
surface	NULL
markers	NULL
,	NULL
c-Kit	NULL
,	NULL
Gr-1	NULL
,	NULL
and	NULL
'	NULL
A	NULL
Mac-1	NULL
,	NULL
conjugated	NULL
with	NULL
fluores-cein	NULL
isothiocyanate	NULL
(	NULL
Mac-1	NULL
)	NULL
or	NULL
mag	NULL
®	NULL
ao	NULL
!	NULL

ao	NULL
``	NULL
40°	NULL
rot	NULL
_io°	NULL
ao	NULL
``	NULL
10	NULL
``	NULL
ron	NULL
as*	NULL
10°	NULL
ao	NULL
``	NULL
aot	NULL
aot	NULL
aot	NULL
_	NULL
10°	NULL
ao	NULL
!	NULL

ao	NULL
``	NULL
a0°	NULL
aot	NULL
§	NULL
C	NULL
To	NULL
?	NULL

of	NULL
aot	NULL
ant	NULL
aot	NULL
ao	NULL
ao	NULL
``	NULL
ao	NULL
``	NULL
dot	NULL
R-phycoerythrin	NULL
(	NULL
others	NULL
)	NULL
(	NULL
solid	NULL
a	NULL
eco	NULL
400	NULL
1200	NULL
..	NULL
0	NULL
8	NULL
7	NULL
8	NULL
18.5	NULL
%	NULL
i	NULL
82.6	NULL
%	NULL
18.2	NULL
%	NULL
32.6	NULL
%	NULL
e	NULL
e	NULL
e	NULL
25	NULL
%	NULL
o	NULL
ase	NULL
lines	NULL
)	NULL
,	NULL
and	NULL
with	NULL
control	NULL
antibod-	NULL
A\	NULL
,	NULL
ies	NULL
of	NULL
the	NULL
same	NULL
isotype	NULL
(	NULL
dotted	NULL
[	NULL
cw	NULL
lines	NULL
)	NULL
.	NULL

Before	NULL
Gr-1	NULL
and	NULL
Mac-1	NULL
=	NULL
r	NULL
ipr	NULL
r	NULL
rgrmng	NULL
grr	NULL
retin	NULL
10°	NULL
ao	NULL
``	NULL
ao	NULL
act	NULL
aot	NULL
16°	NULL
ao	NULL
``	NULL
as	NULL
``	NULL
aot	NULL
aot	NULL
10°	NULL
so	NULL
!	NULL

aot	NULL
ao	NULL
``	NULL
aot	NULL
rot	NULL
ao	NULL
``	NULL
iof	NULL
ro	NULL
ao	NULL
g	NULL
s	NULL
s	NULL
``	NULL
rot	NULL
t	NULL
aL	NULL
*d.	NULL
stfiining	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
g	NULL
with	NULL
CD16/32	NULL
antibody	NULL
to	NULL
block	NULL
400	NULL
§	NULL
B	NULL
&	NULL
&	NULL
8.8	NULL
%	NULL
[	NULL
}	NULL
-	NULL
sas	NULL
%	NULL
17.0	NULL
%	NULL
34.1	NULL
%	NULL
€	NULL
Relative	NULL
-	NULL
cell	NULL
number	NULL
o	NULL
©	NULL
4	NULL
Yano	NULL
,	NULL
0	NULL
Mac-1	NULL
o	NULL
e	NULL
2.4	NULL
%	NULL
-_-	NULL
161	NULL
%	NULL
non-antigen-specific	NULL
binding	NULL
of	NULL
m	NULL
5	NULL
antibodies	NULL
to	NULL
the	NULL
murine	NULL
FeyII/	NULL
10°	NULL
To	NULL
``	NULL
ot	NULL
aot	NULL
ant	NULL
.	NULL

106	NULL
io	NULL
``	NULL
no	NULL
III	NULL
receptors	NULL
.	NULL

Values	NULL
given	NULL
in	NULL
up	NULL
~	NULL
o	NULL
``	NULL
o	NULL
...	NULL
.	NULL

fa	NULL
o	NULL
fool	NULL
.	NULL

mrrmmy	NULL
raid	NULL
ryrmqras	NULL
10°	NULL
ao	NULL
``	NULL
ao	NULL
``	NULL
aot	NULL
aot	NULL
10°	NULL
ao	NULL
``	NULL
aot	NULL
de®	NULL
rot	NULL
10	NULL
``	NULL
no	NULL
``	NULL
isn	NULL
ado	NULL
aot	NULL
ao	NULL
``	NULL
do	NULL
``	NULL
io	NULL
``	NULL
aot	NULL
aot	NULL
Log	NULL
fluorescence	NULL
intensity	NULL
domains	NULL
of	NULL
RARa	NULL
(	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
spite	NULL
of	NULL
their	NULL
diversity	NULL
,	NULL
the	NULL
various	NULL
fusion	NULL
molecules	NULL
share	NULL
one	NULL
common	NULL
feature	NULL
,	NULL
their	NULL
ability	NULL
to	NULL
heterodimerize	NULL
with	NULL
X	NULL
proteins	NULL
,	NULL
because	NULL
the	NULL
regions	NULL
which	NULL
can	NULL
mediate	NULL
X	NULL
protein	NULL
homodimerization	NULL
and	NULL
oligomerization	NULL
are	NULL
retained	NULL
in	NULL
the	NULL
fusion	NULL
moiety	NULL
(	NULL
13-15	NULL
,	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
RARa	NULL
portion	NULL
can	NULL
heterodimerize	NULL
with	NULL
RXR	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
,	NULL
and	NULL
consequently	NULL
,	NULL
the	NULL
various	NULL
fusion	NULL
products	NULL
have	NULL
the	NULL
ability	NULL
to	NULL
interfere	NULL
with	NULL
both	NULL
X	NULL
and	NULL
RAR	NULL
«	NULL
/RXR	NULL
pathways	NULL
.	NULL

Therefore	NULL
,	NULL
X/RARa	NULL
proteins	NULL
can	NULL
dominantly	NULL
interfere	NULL
with	NULL
the	NULL
aforementioned	NULL
activity	NULL
of	NULL
X	NULL
proteins	NULL
as	NULL
well	NULL
as	NULL
with	NULL
their	NULL
and	NULL
RARa	NULL
's	NULL
possible	NULL
involvement	NULL
in	NULL
modulating	NULL
normal	NULL
hemopoietic	NULL
processes	NULL
,	NULL
with	NULL
the	NULL
cooperation	NULL
of	NULL
RARa/X	NULL
and	NULL
aberrant	NULL
X	NULL
products	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
the	NULL
RARa	NULL
&	NULL
/PML	NULL
fusion	NULL
product	NULL
in	NULL
APL	NULL
leukemogenesis	NULL
has	NULL
been	NULL
J	NULL
>	NULL
90	NULL
sel	NULL
/	NULL
.	NULL

30	NULL
a	NULL
e	NULL
20	NULL
w	NULL
10	NULL
Number	NULL
of	NULL
colonies	NULL
Number	NULL
of	NULL
colonies	NULL
a	NULL
cru	NULL
cu	NULL
aruz	NULL
.	NULL

cructin	NULL
camer	NULL
cen	NULL
arve	NULL
.	NULL

Cans	NULL
B	NULL
Bone	NULL
marrow	NULL
Spleen	NULL
a	NULL
$	NULL
O	NULL
RA-go	NULL
®	NULL
M	NULL
RA+	NULL
so	NULL
2	NULL
a	NULL
3	NULL
so	NULL
€	NULL
a	NULL
~-	NULL
E4	NULL
#	NULL
0	NULL
Sos	NULL
-m-	NULL
40	NULL
mo	NULL
as	NULL
£	NULL
20	NULL
4	NULL
5	NULL
20	NULL
2	NULL
S	NULL
=	NULL
w.t	NULL
.	NULL

PMURAR	NULL
«	NULL
wet	NULL
PMURAR	NULL
«	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Colony	NULL
formation	NULL
assay	NULL
on	NULL
BM	NULL
and	NULL
spleen	NULL
cells	NULL
from	NULL
hCG-PML/RARa	NULL
leukemic	NULL
mice	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
and	NULL
sex-	NULL
and	NULL
age-matched	NULL
wild-type	NULL
littermates	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
.	NULL

Cells	NULL
(	NULL
3	NULL
x	NULL
10	NULL
``	NULL
)	NULL
were	NULL
plated	NULL
per	NULL
dish	NULL
in	NULL
0.9	NULL
%	NULL
methylcellulose	NULL
medium	NULL
in	NULL
triplicate	NULL
.	NULL

Colony	NULL
numbers	NULL
shown	NULL
here	NULL
are	NULL
from	NULL
one	NULL
representative	NULL
experiment	NULL
(	NULL
mean	NULL
+	NULL
SD	NULL
from	NULL
the	NULL
triplicate	NULL
)	NULL
.	NULL

CFU-GM	NULL
includes	NULL
CFU-G	NULL
,	NULL
-M	NULL
,	NULL
and	NULL
-GM	NULL
.	NULL

Clusters	NULL
are	NULL
clones	NULL
with	NULL
<	NULL
20	NULL
cells	NULL
,	NULL
often	NULL
observed	NULL
in	NULL
assays	NULL
performed	NULL
on	NULL
cells	NULL
from	NULL
acute	NULL
leukemia	NULL
and	NULL
thought	NULL
to	NULL
represent	NULL
colonies	NULL
of	NULL
leukemic	NULL
origin	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
colony	NULL
formation	NULL
from	NULL
all	NULL
lineages	NULL
decreased	NULL
and	NULL
the	NULL
number	NULL
of	NULL
clusters	NULL
often	NULL
observed	NULL
in	NULL
cultures	NULL
from	NULL
acute	NULL
leukemias	NULL
dramatically	NULL
increased	NULL
in	NULL
BM	NULL
and	NULL
spleen	NULL
cultures	NULL
from	NULL
leukemic	NULL
transgenic	NULL
mice	NULL
.	NULL

(	NULL
B	NULL
)	NULL
In	NULL
vitro	NULL
response	NULL
of	NULL
BM	NULL
cells	NULL
to	NULL
RA	NULL
.	NULL

BM	NULL
cells	NULL
from	NULL
transgenic	NULL
(	NULL
PML/RARa	NULL
)	NULL
and	NULL
wild-type	NULL
(	NULL
W.T	NULL
.	NULL
)	NULL

mice	NULL
were	NULL
incubated	NULL
with	NULL
or	NULL
without	NULL
RA	NULL
.	NULL

Percentages	NULL
of	NULL
mature	NULL
granulocytes	NULL
and	NULL
NBT	NULL
-positive	NULL
cells	NULL
on	NULL
day	NULL
5	NULL
are	NULL
shown	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

Note	NULL
that	NULL
both	NULL
the	NULL
percentage	NULL
of	NULL
mature	NULL
granulocytes	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
NBT-positive	NULL
cells	NULL
from	NULL
leukemic	NULL
transgenic	NULL
mice	NULL
are	NULL
increased	NULL
by	NULL
2-fold	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
RA	NULL
.	NULL

o	NULL
T	NULL
per	NULL
right	NULL
corner	NULL
of	NULL
each	NULL
histogram	NULL
indicate	NULL
the	NULL
positive	NULL
population	NULL
for	NULL
each	NULL
antibody	NULL
.	NULL

2	NULL
recently	NULL
highlighted	NULL
by	NULL
the	NULL
identification	NULL
of	NULL
APL	NULL
cases	NULL
with	NULL
nonreciprocal	NULL
translocations	NULL
resulting	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
fusion	NULL
gene	NULL
but	NULL
lacking	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
gene	NULL
(	NULL
39	NULL
)	NULL
.	NULL

We	NULL
decided	NULL
to	NULL
test	NULL
the	NULL
above	NULL
hypothesis	NULL
in	NULL
vivo	NULL
by	NULL
a	NULL
direct	NULL
genetic	NULL
approach	NULL
and	NULL
on	NULL
a	NULL
comparative	NULL
basis	NULL
by	NULL
generating	NULL
transgenic	NULL
mice	NULL
in	NULL
which	NULL
the	NULL
expression	NULL
of	NULL
all	NULL
these	NULL
various	NULL
molecules	NULL
is	NULL
restricted	NULL
to	NULL
the	NULL
hemopoietic/myeloid	NULL
cellular	NULL
com-partment	NULL
.	NULL

The	NULL
development	NULL
of	NULL
a	NULL
suitable	NULL
vector	NULL
to	NULL
direct	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
to	NULL
the	NULL
hemopoietic/myeloid	NULL
compartment	NULL
was	NULL
dictated	NULL
on	NULL
one	NULL
hand	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
our	NULL
attempt	NULL
to	NULL
generate	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
using	NULL
ubiquitous	NULL
promoters	NULL
was	NULL
unsuccessful	NULL
because	NULL
of	NULL
embryonic	NULL
lethality	NULL
,	NULL
and	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
by	NULL
our	NULL
aim	NULL
to	NULL
target	NULL
the	NULL
transgene	NULL
expression	NULL
specifically	NULL
to	NULL
promyelocytes	NULL
,	NULL
to	NULL
possibly	NULL
elicit	NULL
the	NULL
promyelocytic	NULL
block	NULL
observed	NULL
in	NULL
APL	NULL
.	NULL

We	NULL
therefore	NULL
generated	NULL
a	NULL
cathepsin-G	NULL
minigene	NULL
expression	NULL
vector	NULL
from	NULL
the	NULL
human	NULL
locus	NULL
into	NULL
which	NULL
we	NULL
cloned	NULL
cDNAs	NULL
from	NULL
all	NULL
the	NULL
various	NULL
APL-associated	NULL
products	NULL
as	NULL
well	NULL
as	NULL
the	NULL
Lac-Z	NULL
reporter	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Transgenic	NULL
mice	NULL
expressing	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
gene	NULL
develop	NULL
a	NULL
severe	NULL
myeloproliferative	NULL
disorder	NULL
with	NULL
a	NULL
dramatic	NULL
accumulation	NULL
of	NULL
immature	NULL
myeloid	NULL
precursors	NULL
in	NULL
the	NULL
BM	NULL
and	NULL
lymphoid	NULL
organs	NULL
.	NULL

After	NULL
a	NULL
long	NULL
latency	NULL
period	NULL
(	NULL
>	NULL
12	NULL
months	NULL
)	NULL
,	NULL
approximately	NULL
10	NULL
%	NULL
of	NULL
the	NULL
transgenic	NULL
mice	NULL
from	NULL
two	NULL
independent	NULL
lines	NULL
develop	NULL
an	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
characterized	NULL
by	NULL
features	NULL
that	NULL
are	NULL
distinctive	NULL
of	NULL
APL	NULL
:	NULL
(	NULL
?	NULL
)	NULL

a	NULL
dramatic	NULL
accumulation	NULL
of	NULL
promyelocytes	NULL
in	NULL
the	NULL
BM	NULL
(	NULL
>	NULL
30	NULL
%	NULL
)	NULL
;	NULL
(	NULL
#	NULL
#	NULL
)	NULL
the	NULL
presence	NULL
of	NULL
Auer	NULL
's	NULL
bodies	NULL
within	NULL
the	NULL
cytoplasm	NULL
of	NULL
the	NULL
promyelocytic	NULL
blasts	NULL
;	NULL
and	NULL
(	NULL
¥	NULL
?	NULL
)	NULL

the	NULL
response	NULL
of	NULL
the	NULL
leukemic	NULL
blast	NULL
to	NULL
the	NULL
differentiating	NULL
activity	NULL
of	NULL
RA	NULL
(	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
4	NULL
and	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
this	NULL
leukemia	NULL
,	NULL
the	NULL
white	NULL
cell	NULL
counts	NULL
in	NULL
the	NULL
PB	NULL
(	NULL
WBC	NULL
)	NULL
were	NULL
higher	NULL
than	NULL
those	NULL
in	NULL
classical	NULL
APL	NULL
and	NULL
reminiscent	NULL
of	NULL
the	NULL
human	NULL
``	NULL
variant	NULL
``	NULL
APL	NULL
(	NULL
APL-M3v	NULL
in	NULL
the	NULL
French-American-British	NULL
classification	NULL
;	NULL
see	NULL
Table	NULL
1	NULL
and	NULL
ref	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
both	NULL
in	NULL
the	NULL
myeloproliferative	NULL
and	NULL
the	NULL
leukemic	NULL
phase	NULL
the	NULL
infiltrating	NULL
cellular	NULL
population	NULL
partially	NULL
retains	NULL
the	NULL
ability	NULL
to	NULL
terminally	NULL
differentiate	NULL
toward	NULL
mature	NULL
granulocytes	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
hCG-PML/RARa	NULL
mice	NULL
are	NULL
not	NULL
born	NULL
with	NULL
leukemias	NULL
,	NULL
and	NULL
in	NULL
fact	NULL
present	NULL
a	NULL
long	NULL
preleukemic	NULL
incubation	NULL
period	NULL
,	NULL
suggests	NULL
two	NULL
possible	NULL
interpretations	NULL
that	NULL
are	NULL
not	NULL
mutually	NULL
exclusive	NULL
.	NULL

(	NULL
?	NULL
)	NULL

PML/RARa	NULL
is	NULL
necessary	NULL
,	NULL
but	NULL
not	NULL
sufficient	NULL
,	NULL
to	NULL
cause	NULL
full-blown	NULL
APL	NULL
in	NULL
humans	NULL
also	NULL
;	NULL
additional	NULL
mutations	NULL
are	NULL
needed	NULL
,	NULL
which	NULL
in	NULL
humans	NULL
may	NULL
consist	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
RARa/PML	NULL
and	NULL
aberrant	NULL
PML	NULL
.	NULL

(	NULL
@	NULL
)	NULL
The	NULL
relative	NULL
level	NULL
of	NULL
ex	NULL
Medical	NULL
Sciences	NULL
:	NULL
He	NULL
et	NULL
al	NULL
.	NULL

pression	NULL
of	NULL
the	NULL
PML	NULL
/RARa	NULL
transgene	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
PML	NULL
and	NULL
RARa	NULL
genes	NULL
,	NULL
and/or	NULL
other	NULL
genes	NULL
,	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
confer	NULL
to	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
protein	NULL
the	NULL
ability	NULL
to	NULL
dominantly	NULL
interfere	NULL
with	NULL
their	NULL
functions	NULL
.	NULL

From	NULL
this	NULL
point	NULL
of	NULL
view	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
remember	NULL
that	NULL
the	NULL
15	NULL
;	NULL
17	NULL
translocation	NULL
in	NULL
humans	NULL
reduces	NULL
the	NULL
normal	NULL
PML	NULL
and	NULL
RARa	NULL
genes	NULL
to	NULL
heterozygosity	NULL
,	NULL
whereas	NULL
the	NULL
hCG-PML/RARa	NULL
transgenic	NULL
mice	NULL
still	NULL
carry	NULL
two	NULL
normal	NULL
copies	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

The	NULL
second	NULL
interpretation	NULL
is	NULL
unlikely	NULL
because	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
PML	NULL
/RARa	NULL
transgene	NULL
is	NULL
not	NULL
negligible	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
in	NULL
the	NULL
leukemic	NULL
phase	NULL
,	NULL
and	NULL
high	NULL
enough	NULL
to	NULL
dislocate	NULL
PML	NULL
from	NULL
the	NULL
NBs	NULL
,	NULL
an	NULL
event	NULL
observed	NULL
in	NULL
the	NULL
blasts	NULL
of	NULL
APL	NULL
patients	NULL
and	NULL
thought	NULL
to	NULL
be	NULL
pathognomonic	NULL
for	NULL
the	NULL
disease	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
D	NULL
and	NULL
E	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
PML	NULL
/RARa	NULL
seems	NULL
sufficient	NULL
to	NULL
cause	NULL
the	NULL
myeloproliferative	NULL
disorder	NULL
and	NULL
the	NULL
block	NULL
of	NULL
maturation	NULL
because	NULL
this	NULL
is	NULL
observed	NULL
in	NULL
100	NULL
%	NULL
of	NULL
transgenic	NULL
mice	NULL
.	NULL

The	NULL
expansion	NULL
of	NULL
the	NULL
promyelocytic	NULL
cellular	NULL
compartment	NULL
would	NULL
then	NULL
favor	NULL
the	NULL
occurrence	NULL
of	NULL
additional	NULL
transforming	NULL
events	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
interbreeding	NULL
of	NULL
PML	NULL
RARa/PML	NULL
,	NULL
and	NULL
aberrant	NULL
PML	NULL
transgenic	NULL
mice	NULL
will	NULL
allow	NULL
us	NULL
to	NULL
understand	NULL
if	NULL
all	NULL
these	NULL
molecules	NULL
are	NULL
concomitantly	NULL
necessary	NULL
to	NULL
trigger	NULL
full-blown	NULL
leukemia	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
to	NULL
test	NULL
if	NULL
the	NULL
lack	NULL
of	NULL
PML	NULL
and	NULL
RARa	NULL
,	NULL
and	NULL
therefore	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
genes	NULL
and	NULL
fusion	NULL
genes	NULL
,	NULL
potentiates	NULL
the	NULL
leukemogenic	NULL
activity	NULL
of	NULL
the	NULL
APL-specific	NULL
fusion	NULL
molecules	NULL
,	NULL
we	NULL
have	NULL
interbred	NULL
the	NULL
PML	NULL
/	NULL
RARa	NULL
transgenic	NULL
mice	NULL
with	NULL
PML	NULL
and	NULL
RARa	NULL
knockout	NULL
mice	NULL
.	NULL

Transgenic	NULL
mice	NULL
for	NULL
the	NULL
PML/RARa	NULL
fusion	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
myeloid	NULL
CD11b	NULL
promoter	NULL
did	NULL
not	NULL
develop	NULL
leukemia	NULL
over	NULL
the	NULL
course	NULL
of	NULL
a	NULL
more	NULL
than	NULL
2-year	NULL
follow-up	NULL
period	NULL
and	NULL
total	NULL
WBC	NULL
and	NULL
differential	NULL
counts	NULL
of	NULL
myeloid	NULL
subpopulations	NULL
did	NULL
not	NULL
show	NULL
appreciable	NULL
differences	NULL
between	NULL
PML/RARa	NULL
and	NULL
control	NULL
mice	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Appropriate	NULL
timing	NULL
of	NULL
PML/RARa	NULL
expression	NULL
in	NULL
early	NULL
myeloid	NULL
progenitors	NULL
certainly	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
with	NULL
respect	NULL
to	NULL
its	NULL
leukemogenic	NULL
potential	NULL
and	NULL
its	NULL
ability	NULL
to	NULL
interfere	NULL
with	NULL
normal	NULL
hematopoiesis	NULL
,	NULL
thus	NULL
possibly	NULL
explaining	NULL
the	NULL
difference	NULL
observed	NULL
with	NULL
our	NULL
mice	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
retrovirally	NULL
mediated	NULL
expression	NULL
of	NULL
a	NULL
mutated	NULL
version	NULL
of	NULL
PML/RARa	NULL
in	NULL
the	NULL
chicken	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
cause	NULL
leukemias	NULL
,	NULL
but	NULL
the	NULL
cells	NULL
exhibit	NULL
features	NULL
and	NULL
membrane	NULL
antigen	NULL
patterns	NULL
of	NULL
very	NULL
immature	NULL
cells	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
reasons	NULL
why	NULL
the	NULL
chicken	NULL
leukemic	NULL
cells	NULL
are	NULL
different	NULL
from	NULL
the	NULL
human	NULL
APL	NULL
cells	NULL
are	NULL
unknown	NULL
,	NULL
although	NULL
the	NULL
specific	NULL
phenotype	NULL
might	NULL
be	NULL
a	NULL
result	NULL
of	NULL
the	NULL
two	NULL
point	NULL
mutations	NULL
present	NULL
in	NULL
the	NULL
PML/RARa	NULL
«	NULL
fusion	NULL
protein	NULL
that	NULL
was	NULL
used	NULL
in	NULL
those	NULL
studies	NULL
(	NULL
42	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
in	NULL
our	NULL
transgenic	NULL
mice	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
PML/	NULL
RARa	NULL
fusion	NULL
protein	NULL
in	NULL
the	NULL
myeloid	NULL
compartment	NULL
resulted	NULL
in	NULL
profound	NULL
disturbances	NULL
in	NULL
myeloid	NULL
hematopoiesis	NULL
and	NULL
in	NULL
myeloid	NULL
leukemias	NULL
characterized	NULL
by	NULL
a	NULL
block	NULL
of	NULL
differentiation	NULL
at	NULL
the	NULL
promyelocytic	NULL
stage	NULL
that	NULL
defines	NULL
the	NULL
APL	NULL
phenotype	NULL
.	NULL

Thus	NULL
,	NULL
our	NULL
data	NULL
conclusively	NULL
demonstrate	NULL
in	NULL
vivo	NULL
that	NULL
PML/RARa	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
APL	NULL
pathogenesis	NULL
.	NULL

The	NULL
comparative	NULL
analysis	NULL
of	NULL
PML/RARa	NULL
,	NULL
PLZF/RARa	NULL
,	NULL
NPM/RAR	NULL
«	NULL
,	NULL
and	NULL
NUMA/RARa	NULL
transgenic	NULL
mice	NULL
will	NULL
tell	NULL
us	NULL
how	NULL
the	NULL
various	NULL
fusion	NULL
molecules	NULL
contribute	NULL
to	NULL
the	NULL
leukemic	NULL
phenotype	NULL
,	NULL
and	NULL
whether	NULL
they	NULL
cause	NULL
a	NULL
more	NULL
severe	NULL
or	NULL
benign	NULL
phenotype	NULL
,	NULL
also	NULL
with	NULL
respect	NULL
to	NULL
their	NULL
response	NULL
to	NULL
RA	NULL
treatment	NULL
.	NULL

We	NULL
thank	NULL
P.	NULL
Freemont	NULL
for	NULL
the	NULL
PML	NULL
antibody	NULL
;	NULL
L.	NULL
Luzzatto	NULL
for	NULL
critical	NULL
reviewing	NULL
of	NULL
the	NULL
manuscript	NULL
;	NULL
N.	NULL
Hawe	NULL
and	NULL
V.	NULL
Petronis	NULL
for	NULL
help	NULL
with	NULL
the	NULL
editing	NULL
of	NULL
the	NULL
manuscript	NULL
;	NULL
D.	NULL
Gandini	NULL
,	NULL
R.	NULL
Notaro	NULL
,	NULL
and	NULL
V.	NULL
Rosti	NULL
for	NULL
help	NULL
with	NULL
some	NULL
experiments	NULL
and	NULL
critical	NULL
support	NULL
;	NULL
and	NULL
Jia	NULL
Hui	NULL
Dong	NULL
for	NULL
assistance	NULL
with	NULL
the	NULL
management	NULL
of	NULL
the	NULL
mice	NULL
.	NULL

R.R	NULL
.	NULL

was	NULL
partially	NULL
supported	NULL
by	NULL
the	NULL
Associazione	NULL
Italiana	NULL
per	NULL
la	NULL
Ricerca	NULL
sul	NULL
Cancro	NULL
.	NULL

G.C	NULL
.	NULL

is	NULL
a	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
Special	NULL
Fellow	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Sloan-Kettering	NULL
Institute	NULL
and	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
P.P.P	NULL
.	NULL
)	NULL

.	NULL

1	NULL
.	NULL

Bennett	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Catovsky	NULL
,	NULL
D.	NULL
,	NULL
Daniel	NULL
,	NULL
D.	NULL
,	NULL
Flandrin	NULL
,	NULL
G.	NULL
,	NULL
Galton	NULL
,	NULL
D.	NULL
A.	NULL
G.	NULL
,	NULL
Gralnick	NULL
,	NULL
H.	NULL
R.	NULL
&	NULL
Sultan	NULL
,	NULL
C.	NULL
(	NULL
1976	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Haematol	NULL
.	NULL

33	NULL
,	NULL
451-458	NULL
.	NULL

2	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
Haematologica	NULL
81	NULL
,	NULL
472-482	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
5307	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Longo	NULL
,	NULL
L.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Donti	NULL
,	NULL
E.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Blood	NULL
83	NULL
,	NULL
10-25	NULL
.	NULL

Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
de	NULL
Thé	NULL
,	NULL
H.	NULL
,	NULL
Wang	NULL
,	NULL
Z.	NULL
Y	NULL
.	NULL

&	NULL
Degos	NULL
,	NULL
L.	NULL
(	NULL
1993	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

329	NULL
,	NULL
177-189	NULL
.	NULL

Longo	NULL
,	NULL
L.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Rambaldi	NULL
,	NULL
A.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Diverio	NULL
,	NULL
D.	NULL
,	NULL
Pegoraro	NULL
,	NULL
L.	NULL
,	NULL
Avanzi	NULL
,	NULL
G.	NULL
,	NULL
Tabilio	NULL
,	NULL
A.	NULL
,	NULL
Zangrilli	NULL
,	NULL
D.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Donti	NULL
,	NULL
E.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1571-1575	NULL
.	NULL

Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Zangrilli	NULL
,	NULL
D.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Longo	NULL
,	NULL
L.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Giacomucci	NULL
,	NULL
A.	NULL
,	NULL
Rocchi	NULL
,	NULL
M.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Rambaldi	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Diverio	NULL
,	NULL
D.	NULL
,	NULL
Donti	NULL
,	NULL
E.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
1977-1981	NULL
.	NULL

Borrow	NULL
,	NULL
J.	NULL
,	NULL
Goddard	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Sheer	NULL
,	NULL
D.	NULL
&	NULL
Solomon	NULL
,	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
249	NULL
,	NULL
1577-1580.	NULL
de	NULL
Thé	NULL
,	NULL
H.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
347	NULL
,	NULL
558-561	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
1285-1292	NULL
.	NULL

Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Murty	NULL
,	NULL
V.	NULL
V.	NULL
V.	NULL
S.	NULL
,	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
663-674.	NULL
de	NULL
Thé	NULL
,	NULL
H.	NULL
,	NULL
Lavau	NULL
,	NULL
C.	NULL
,	NULL
Marchio	NULL
,	NULL
A.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
675-684	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Zangrilli	NULL
,	NULL
D.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Diverio	NULL
,	NULL
D.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Rambaldi	NULL
,	NULL
A.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Rochette-Egly	NULL
,	NULL
C.	NULL
,	NULL
Gaub	NULL
,	NULL
M.-P.	NULL
,	NULL
Chambon	NULL
,	NULL
P.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
1397-1407	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
Brand	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Chen	NULL
,	NULL
A.	NULL
,	NULL
Chen	NULL
,	NULL
S.-J	NULL
.	NULL

,	NULL
Tong	NULL
,	NULL
J.-H.	NULL
,	NULL
Wang	NULL
,	NULL
Z.-Y	NULL
.	NULL

,	NULL
Waxman	NULL
,	NULL
S.	NULL
&	NULL
Zelent	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
1161-1167	NULL
.	NULL

Redner	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Rush	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Faas	NULL
,	NULL
S.	NULL
,	NULL
Rudert	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

&	NULL
Corey	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Blood	NULL
3	NULL
,	NULL
882-886	NULL
.	NULL

Wells	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

&	NULL
Kamel-Reid	NULL
,	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
Blood	NULL
88	NULL
,	NULL
365	NULL
(	NULL
abstr	NULL
.	NULL
)	NULL

.	NULL

Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Zangrilli	NULL
,	NULL
D.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Biondi	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
4840-4844	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
,	NULL
Perez	NULL
,	NULL
A.	NULL
,	NULL
Lutz	NULL
,	NULL
Y.	NULL
,	NULL
Rochette-Egly	NULL
,	NULL
C.	NULL
,	NULL
Gaub	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Durand	NULL
,	NULL
B.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
&	NULL
Chambon	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
629-642	NULL
.	NULL

Perez	NULL
,	NULL
A.	NULL
,	NULL
Kastner	NULL
,	NULL
P.	NULL
,	NULL
Sethi	NULL
,	NULL
S.	NULL
,	NULL
Lutz	NULL
,	NULL
Y.	NULL
,	NULL
Reibel	NULL
,	NULL
C.	NULL
&	NULL
Chambon	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
3171-3182	NULL
.	NULL

Dyck	NULL
,	NULL
J.	NULL
,	NULL
Maul	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Chen	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
333-343	NULL
.	NULL

Koken	NULL
,	NULL
M.	NULL
H.	NULL
M.	NULL
,	NULL
Puvion-Dutilleul	NULL
,	NULL
F.	NULL
,	NULL
Guillemin	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Viron	NULL
,	NULL
A.	NULL
,	NULL
Linares-Cruz	NULL
,	NULL
G.	NULL
,	NULL
Stuurman	NULL
,	NULL
N.	NULL
,	NULL
de	NULL
Jong	NULL
,	NULL
L.	NULL
,	NULL
Szostecki	NULL
,	NULL
C.	NULL
,	NULL
Calvo	NULL
,	NULL
F.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
Puvion	NULL
,	NULL
E.	NULL
&	NULL
de	NULL
Thé	NULL
,	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

13	NULL
,	NULL
1073-1083	NULL
.	NULL

Weis	NULL
,	NULL
K.	NULL
,	NULL
Rambaud	NULL
,	NULL
S.	NULL
,	NULL
Lavau	NULL
,	NULL
C.	NULL
,	NULL
Jansen	NULL
,	NULL
J.	NULL
,	NULL
Carvalho	NULL
,	NULL
T.	NULL
,	NULL
Carmo-Fonseca	NULL
,	NULL
M.	NULL
,	NULL
Lamond	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
345-356	NULL
.	NULL

Mu	NULL
,	NULL
Z.-M.	NULL
,	NULL
Chin	NULL
,	NULL
K.-V.	NULL
,	NULL
Liu	NULL
,	NULL
J.-H.	NULL
,	NULL
Lozano	NULL
,	NULL
G.	NULL
&	NULL
Chang	NULL
,	NULL
K.-S.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
6858-6867	NULL
.	NULL

Koken	NULL
,	NULL
M.	NULL
H.	NULL
M.	NULL
,	NULL
Linares-Cruz	NULL
,	NULL
G.	NULL
,	NULL
Quignon	NULL
,	NULL
F.	NULL
,	NULL
Viron	NULL
,	NULL
A.	NULL
,	NULL
Chelbi-Alix	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Sobczak-Thepot	NULL
,	NULL
J.	NULL
,	NULL
Juhlin	NULL
,	NULL
L.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
Calvo	NULL
,	NULL
F.	NULL
&	NULL
de	NULL
Thé	NULL
,	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
Oncogene	NULL
10	NULL
,	NULL
1315-1324	NULL
.	NULL

Collins	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Robertson	NULL
,	NULL
K.	NULL
&	NULL
Mueller	NULL
,	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
2154-2163	NULL
.	NULL

Robertson	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Emami	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Blood	NULL
80	NULL
,	NULL
1885-1889	NULL
.	NULL

Tsai	NULL
,	NULL
S.	NULL
,	NULL
Bartelmez	NULL
,	NULL
S.	NULL
,	NULL
Heyman	NULL
,	NULL
R.	NULL
,	NULL
Damm	NULL
,	NULL
K.	NULL
,	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

6	NULL
,	NULL
2258-2269	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
Ferruceci	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
Testa	NULL
,	NULL
U.	NULL
,	NULL
Talamo	NULL
,	NULL
G.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Peschle	NULL
,	NULL
C.	NULL
,	NULL
Nicoletti	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Cell	NULL
74	NULL
,	NULL
423-431	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
Testa	NULL
,	NULL
U.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Barberi	NULL
,	NULL
T.	NULL
,	NULL
Masciulli	NULL
,	NULL
R.	NULL
,	NULL
Mariani	NULL
,	NULL
G.	NULL
,	NULL
Peschle	NULL
,	NULL
C.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

55	NULL
,	NULL
440-443	NULL
.	NULL

Rousselot	NULL
,	NULL
P.	NULL
,	NULL
Hardas	NULL
,	NULL
B.	NULL
,	NULL
Patel	NULL
,	NULL
A.	NULL
,	NULL
Guidez	NULL
,	NULL
F.	NULL
,	NULL
Giken	NULL
,	NULL
J.	NULL
,	NULL
Castaigne	NULL
,	NULL
S.	NULL
,	NULL
Dejean	NULL
,	NULL
A.	NULL
,	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
Farzanceh	NULL
,	NULL
F.	NULL
&	NULL
Chomienne	NULL
,	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Oncogene	NULL
9	NULL
,	NULL
545-551	NULL
.	NULL

Hohn	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Popescu	NULL
,	NULL
N.C.	NULL
,	NULL
Hanson	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Salvesen	NULL
,	NULL
G.	NULL
&	NULL
Ley	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
13412-13419	NULL
.	NULL

Hogan	NULL
,	NULL
B.	NULL
,	NULL
Beddington	NULL
,	NULL
R.	NULL
,	NULL
Costantini	NULL
,	NULL
F.	NULL
&	NULL
Lacy	NULL
,	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Manipulating	NULL
the	NULL
Mouse	NULL
Embryo	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Lab	NULL
.	NULL

Press	NULL
,	NULL
Plainview	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
2nd	NULL
Ed	NULL
.	NULL

,	NULL
pp	NULL
.	NULL

226-250	NULL
.	NULL

Chomezynski	NULL
,	NULL
P.	NULL
&	NULL
Sacchi	NULL
,	NULL
N.	NULL
(	NULL
1987	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162	NULL
,	NULL
156-159	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Lab	NULL
.	NULL

Press	NULL
,	NULL
Plainview	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
2nd	NULL
Ed	NULL
.	NULL

Seale	NULL
,	NULL
J.	NULL
R.	NULL
C.	NULL
,	NULL
Varma	NULL
,	NULL
S.	NULL
,	NULL
Swirsky	NULL
,	NULL
D.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Goldman	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
Cross	NULL
,	NULL
N.	NULL
C.	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Haematol	NULL
.	NULL

95	NULL
,	NULL
95-101	NULL
.	NULL

Cattoretti	NULL
,	NULL
G.	NULL
,	NULL
Chang	NULL
,	NULL
C.-C.	NULL
,	NULL
Cechova	NULL
,	NULL
K.	NULL
,	NULL
Zhang	NULL
,	NULL
J.	NULL
,	NULL
Ye	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Falini	NULL
,	NULL
B.	NULL
,	NULL
Louie	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Offit	NULL
,	NULL
K.	NULL
,	NULL
Chaganti	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
&	NULL
Dalla-Favera	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
86	NULL
,	NULL
45-53	NULL
.	NULL

Grisolano	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Sclar	NULL
,	NULL
G.	NULL
M.	NULL
&	NULL
Ley	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
8989-8993	NULL
.	NULL

Moore	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Spitzer	NULL
,	NULL
G.	NULL
,	NULL
Williams	NULL
,	NULL
N.	NULL
,	NULL
Metcalf	NULL
D.	NULL
&	NULL
Buckley	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1974	NULL
)	NULL
Blood	NULL
44	NULL
,	NULL
1-18	NULL
.	NULL

Castaigne	NULL
,	NULL
S.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
,	NULL
Fenaux	NULL
,	NULL
P.	NULL
&	NULL
Degos	NULL
,	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
Blood	NULL
76	NULL
,	NULL
1704-1709	NULL
.	NULL

Lafage-Pochitaloff	NULL
,	NULL
M.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Brunnel	NULL
,	NULL
V.	NULL
,	NULL
Longo	NULL
,	NULL
L.	NULL
,	NULL
Sainty	NULL
,	NULL
D.	NULL
,	NULL
Simonetti	NULL
,	NULL
J.	NULL
,	NULL
Birg	NULL
,	NULL
F.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
85	NULL
,	NULL
1169-1174	NULL
.	NULL

Luzzatto	NULL
,	NULL
L.	NULL
&	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Br	NULL
.	NULL

Med	NULL
.	NULL

J	NULL
.	NULL

307	NULL
,	NULL
579-580	NULL
.	NULL

Early	NULL
,	NULL
E.	NULL
,	NULL
Moore	NULL
,	NULL
M.	NULL
A.	NULL
S.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Nason-Burchenal	NULL
,	NULL
K.	NULL
,	NULL
Martin	NULL
,	NULL
P.	NULL
,	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
,	NULL
7900-7904	NULL
.	NULL

Altabef	NULL
,	NULL
M.	NULL
,	NULL
Garcia	NULL
,	NULL
M.	NULL
,	NULL
Lavau	NULL
,	NULL
C.	NULL
,	NULL
Bac	NULL
,	NULL
S.-C.	NULL
,	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Samarut	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

15	NULL
,	NULL
2707-2716	NULL
.	NULL

